Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits

ABSTRACT

Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.

FIELD OF THE INVENTION

The invention relates to the isolation, characterization and utilization of the causative agent of the Mystery Swine Disease (MSD). The invention utilizes the discovery of the agent causing the disease and the determination of its genome organization, the genomic nucleotide sequence and the proteins encoded by the genome, for providing protection against and diagnosis of infections, in particular protection against and diagnosis of MSD infections, and for providing vaccine compositions and diagnostic kits, either for use with MSD or with other pathogen-caused diseases.

BACKGROUND

In the winter and early spring of 1991, the Dutch pig industry was struck by a sudden outbreak of a new disease among breeding sows. Most sows showed anorexia, some aborted late in gestation (around day 110), showed stillbirths or gave birth to mummified fetuses and some had fever. Occasionally, sows with bluish ears were found, therefore the disease was commonly named "Abortus Blauw". The disease in the sows was often accompanied by respiratory distress and death of their young piglets, and often by respiratory disease and growth retardation of older piglets and fattening pigs.

The cause of this epizootic was not known, but the symptoms resembled those of a similar disease occurring in Germany since late 1990, and resembled those of the so-called "Mystery Swine Disease" as seen since 1987 in the mid-west of the United States of America and in Canada (Hill, 1990). Various other names have been used for the disease, in Germany it is known as "Seuchenhafter Sp atabort der Schweine", and in North-America it is also known as "Mystery Pig Disease", "Mysterious Reproductive Syndrome", and "Swine Infertility and Respiratory Syndrome". In North-America, Loula (1990) described the general clinical signs as:

1) Off feed, sick animals of all ages

2) Abortions, stillbirths, weak pigs, mummies

3) Post farrowing respiratory problems

4) Breeding problems.

No causative agent has as yet been identified, but encephalomyocarditis virus (EMCV), porcine parvo virus (PPV), pseudorabies virus (PRV), swine influenza virus (SIV), bovine viral diarrhea virus (BVDV), hog cholera virus (HCV), porcine entero viruses (PEV), an influenza-like virus, chlamidiae, leptospirae, have all been named as possible cause (Loula, 1990; Mengeling and Lager, 1990; among others).

SUMMARY OF THE INVENTION

The invention provides a composition of matter comprising isolated Lelystad Agent which is the causative agent of Mystery Swine Disease, said Lelystad Agent essentially corresponding to the isolate Lelystad Agent (CDI-NL-2.91) deposited 5 Jun. 1991 with the Institut Pasteur, Collection Nationale de Cultures De Microorganismes (C.N.C.M.) 25, rue du Docteur Roux, 75724-Paris Cedex 15, France, deposit number I-1102. The words "essentially corresponding" refer to variations that occur in nature and to artificial variations of Lelystad Agent, particularly those which still allow detection by techniques like hybridization, PCR and ELISA, using Lelystad Agent-specific materials, such as Lelystad Agent-specific DNA or antibodies.

The composition of matter may comprise live, killed, or attenuated isolated Lelystad Agent; a recombinant vector derived from Lelystad Agent; an isolated part or component of Lelystad Agent; isolated or synthetic protein, (poly)peptide, or nucleic acid derived from Lelystad Agent; recombinant nucleic acid which comprises a nucleotide sequence derived from the genome of Lelystad Agent; a (poly)peptide having an amino acid sequence derived from a protein of Lelystad Agent, the (poly)peptide being produced by a cell capable of producing it due to genetic engineering with appropriate recombinant DNA; an isolated or synthetic antibody which specifically recognizes a part or component of Lelystad Agent; or a recombinant vector which contains nucleic acid comprising a nucleotide sequence coding for a protein or antigenic peptide derived from Lelystad Agent.

On the DNA level, the invention specifically provides a recombinant nucleic acid, more specifically recombinant DNA, which comprises a Lelystad Agent-specific nucleotide sequence shown in FIG. 1 which includes FIGS. 1a through 1q (SEQ ID NO: 1). Preferably, said Lelystad Agent-specific nucleotide sequence is selected from anyone of the ORFs (Open Reading Frames) shown in FIG. 1 (SEQ ID NO: 1).

On the peptide/protein level, the invention specifically provides a peptide comprising a Lelystad Agent-specific amino acid sequence shown in FIG. 1.

The invention further provides a vaccine composition for vaccinating animals, in particular mammals, more in particular pigs or swines, to protect them against Mystery Swine Disease, comprising Lelystad Agent, either live, killed, or attenuated; or a recombinant vector which contains nucleic acid comprising a nucleotide sequence coding for a protein or antigenic peptide derived from Lelystad Agent; an antigenic part or component of Lelystad Agent; a protein or antigenic polypeptide derived from, or a peptide mimicking an antigenic component of, Lelystad Agent; and a suitable carrier or adjuvant.

The invention also provides a vaccine composition for vaccinating animals, in particular mammals, more in particular pigs or swines, to protect them against a disease caused by a pathogen, comprising a recombinant vector derived from Lelystad Agent, the nucleic acid of the recombinant vector comprising a nucleotide sequence coding for a protein or antigenic peptide derived from the pathogen, and a suitable carrier or adjuvant.

The invention further provides a diagnostic kit for detecting nucleic acid from Lelystad Agent in a sample, in particular a biological sample such as blood or blood serum, sputum, saliva, or tissue, derived from an animal, in particular a mammal, more in particular a pig or swine, comprising a nucleic acid probe or primer which comprises a nucleotide sequence derived from the genome of Lelystad Agent, and suitable detection means of a nucleic acid detection assay.

The invention also provides a diagnostic kit for detecting antigen from Lelystad Agent in a sample, in particular a biological sample such as blood or blood serum, sputum, saliva, or tissue, derived from an animal, in particular a mammal, more in particular a pig or swine, comprising an antibody which specifically recognizes a part or component of Lelystad Agent, and suitable detection means of an antigen detection assay.

The invention also provides a diagnostic kit for detecting an antibody which specifically recognizes Lelystad Agent in a sample, in particular a biological sample such as blood or blood serum, sputum, saliva, or tissue, derived from an animal, in particular a mammal, more in particular a pig or swine, comprising Lelystad Agent; an antigenic part or component of Lelystad Agent; a protein or antigenic polypeptide derived from Lelystad Agent; or a peptide mimicking an antigenic component of Lelystad Agent; and suitable detection means of an antibody detection assay.

The invention also relates to a process for diagnosing whether an animal, in particular a mammal, more in particular a pig or swine, is contaminated with the causative agent of Mystery Swine Disease, comprising preparing a sample, in particular a biological sample such as blood or blood serum, sputum, saliva, or tissue, derived from the animal, and examining whether it contains Lelystad Agent nucleic acid, Lelystad Agent antigen, or antibody specifically recognizing Lelystad Agent, said Lelystad Agent being the causative agent of Mystery Swine Disease and essentially corresponding to the isolate Lelystad Agent (CDI-NL-2.91) deposited 5 Jun. 1991 with the Institut Pasteur, Paris, France, deposit number I-1102.

DETAILED DESCRIPTION OF THE INVENTION

The invention is a result of combined efforts of the Central Veterinary Institute (CVI) and the Regional Animal Health Services (RAHS) in the Netherlands in trying to find the cause of the new disease MSD. Farms with pigs affected by the new disease were visited by field veterinarians of the RAHS. Sick pigs, specimens of sick pigs, and sow sera taken at the time of the acute and convalescent phase of the disease were sent for virus isolation to the RAHS and the CVI. Paired sera of affected sows were tested for antibodies against ten known pig-viruses. Three different viruses, encephalomyocarditis virus, porcine entero virus type 2, porcine entero virus type 7, and an unknown agent, Lelystad agent (LA), were isolated. Sows which had reportedly been struck with the disease mainly seroconverted to LA, and hardly to any of the other virus isolates or the known viral pathogens. In order to reproduce MSD experimentally, eight pregnant sows were inoculated intranasally with LA at day 84 of gestation. One sow gave birth to seven dead and four live but very weak piglets at day 109 of gestation; the four live piglets died one day after birth. Another sow gave birth at day 116 to three mummified fetuses, six dead piglets and three live piglets; two of the live piglets died within one day. A third sow gave birth at day 117 to two mummified fetuses, eight dead and seven live piglets. The other sows farrowed around day 115 and had less severe reproductive losses. The mean number of live piglets from all eight sows at birth was 7.3 and the mean number of dead piglets at birth was 4.6. Antibodies directed against LA were detected in 10 out of 42 serum samples collected before the pigs had sucked. LA was isolated from three piglets that died shortly after birth. These results justify the conclusion that LA is the causal agent of mystery swine disease.

LA grows with a cytopathic effect in pig lung macrophages and can be identified by staining in an immuno-peroxidase-monolayer assay (IPMA) with postinfection sera of pigs c 829 and b 822, or with any of the other postinfection sera of the SPF pigs listed in table 5. Antibodies to LA can be identified by indirect staining procedures in IPMA. LA did not grow in any other cell system tested. LA was not neutralized by homologous sera, or by sera directed against a set of known viruses (Table 3). LA did not haemagglutinate with the red blood cells tested. LA is smaller than 200 nm since it passes through a filter with pores of this size. LA is sensitive to chloroform. The above results show that Lelystad agent is not yet identified as belonging to a certain virus group or other microbiological species. It has been deposited 5 Jun. 1991 under number I-1102 at Institute Pasteur, France.

The genome organization, nucleotide sequences, and polypeptides derived therefrom, of LA have now been found. These data together with those of others (see below) justify classification of LA (hereafter also called Lelystad Virus or LV) as a member of a new virus family, the Arteriviridae. As prototype virus of this new family we propose Equine Arteritis Virus (EAV), the first member of the new family of which data regarding the replication strategy of the genome and genome organization became available (de Vries et al., 1990, and references therein). On the basis of a comparison of our sequence data with those available for Lactate Dehydrogenase-Elevating Virus (LDV; Godeny et al., 1990), we propose that LDV is also a member of the Arteriviridae.

Given the genome organization and translation strategy of Arteriviridae it seems appropriate to place this new virus family into the superfamily of coronaviruses (Snijder et al., 1990a).

Arteriviruses have in common that their primary target cells in respective hosts are macrophages. Replication of LDV has been shown to be restricted to macrophages in its host, the mouse, whereas this strict propensity for macrophages has not been resolved yet for EAV, and LV.

Arteriviruses are spherical enveloped particles having a diameter of 45-60 nm and containing an icosahedral nucleocapsid (Brinton-Darnell and Plagemann, 1975; Horzinek et al., 1971; Hyllseth, 1973).

The genome of Arteriviridae consists of a positive stranded polyadenylated RNA molecule with a size of about 12-13 kilobases (kb) (Brinton-Darnell and Plageman, 1975; van der Zeijst et al., 1975). EAV replicates via a 3' nested set of six subgenomic mRNAs, ranging in size from 0.8 to 3.6 kb, which are composed of a leader sequence, derived from the 5' end of the genomic RNA, which is joined to the 3' terminal body sequences (de Vries et al., 1990).

Here we show that the genome organization and replication strategy of LV is similar to that of EAV, coronaviruses and toroviruses, whereas the genome sizes of the latter viruses are completely different from those of LV and EAV.

The genome of LV consists of a genomic RNA molecule of about 14.5 to 15.5 kb in length (estimated on a neutral agarose gel), which replicates via a 3' nested set of subgenomic RNAs. The subgenomic RNAs consist of a leader sequence, the length of which is yet unknown, which is derived from the 5' end of the genomic RNA and which is fused to the body sequences derived from the 3' end of the genomic RNA (FIG. 2).

The nucleotide sequence of the genomic RNA of LV was determined from overlapping cDNA clones. A consecutive sequence of 15,088 bp was obtained covering nearly the complete genome of LV (FIG. 1 (SEQ ID NO: 1)). In this sequence 8 open reading frames (ORFs) were identified: ORF 1A, ORF 1B, and ORFs 2 to 7.

ORF 1A and ORF 1B are predicted to encode the viral replicase or polymerase (SEQ ID NO: 2) and (SEQ ID NO: 3), whereas ORFs 2 to 6 are predicted to encode structural viral membrane (envelope) associated proteins (SEQ ID NOS: 4-8). ORF 7 is predicted to encode the structural viral nucleocapsid protein (SEQ ID NO: 9).

Because the products of ORF 6 and ORF 7 of LV (SEQ ID NO: 8) and (SEQ ID NO: 9) show a significant similarity with VpX and Vp1 of LDV respectively, it is predicted that the sequences of ORFs 6 and 7 will also be highly conserved among antigenic variants of LV.

The complete nucleotide sequence of FIG. 1 (SEQ ID NO: 1) and all the sequences and protein products encoded by ORFs 1 to 7 (SEQ ID NOS: 1-9) and possible other ORFs located in the sequence of FIG. 1 (SEQ ID NO: 1), are especially suited for vaccine development, in whatever sense, and for the development of diagnostic tools, in whatever sense. All possible modes are well known to persons skilled in the art.

Since it is now possible to unambiguously identify LA, the causal agent of MSD, it can now be tested whether pigs are infected with LA or not. Such diagnostic tests have until now not been available.

The test can be performed by virus isolation in macro-phages, or other cell culture systems in which LA might grow, and staining the infected cultures with antibodies directed against LA (such as postinfection sera c 829 or b 822), but it is also feasible to develop and employ other types of diagnostic tests.

For instance, it is possible to use direct or indirect immunohistological staining techniques, i.e. with antibodies directed to LA that are labeled with fluorescent compounds such as isothiocyanate, or labeled with enzymes such as horseradish peroxidase. These techniques can be used to detect LA antigen in tissue sections or other samples from pigs suspected to have MSD. The antibodies needed for these tests can be c 829 or b 822 or other polyclonal antibodies directed against LA, but monoclonal antibodies directed against LA can also be used.

Furthermore, since the nature and organization of the genome of LA and the nucleotide sequence of this genome have been determined, LA specific nucleotide sequences can be identified and used to develop oligonucleotide sequences that can be used as probes or primers in diagnostic techniques such as hybridization, polymerase chain reaction, or any other techniques that are developed to specifically detect nucleotide acid sequences.

It is also possible to test for antibodies directed against LA. Table 5 shows that experimentally infected pigs rapidly develop antibodies against LA, and table 4 shows that pigs in the field also have strong antibody responses against LA. Thus it can now also be determined whether pigs have been infected with LA in the past. Such testing is of utmost importance in determining whether pigs or pig herds or pig populations or pigs in whole regions or countries are free of LA. The test can be done by using the IPMA as described, but it is also feasible to develop and employ other types of diagnostic tests for the detection of antibodies directed against LA.

LA specific proteins, polypeptides, and peptides, or peptide sequences mimicking antigenic components of LA, can be used in such tests. Such proteins can be derived from the LA itself, but it is also possible to make such proteins by recombinant DNA or peptide synthesis techniques. These tests can use specific polyclonal and/or monoclonal antibodies directed against LA or specific components of LA, and/or use cell systems infected with LA or cell systems expressing LA antigen. The antibodies can be used, for example, as a means for immobilizing the LA antigen (a solid surface is coated with the antibody whereafter the LA antigen is bound by the antibody) which leads to a higher specificity of the test, or can be used in a competitive assay (labeled antibody and unknown antibody in the sample compete for available LA antigen).

Furthermore, the above described diagnostic possibilities can be applied to test whether other animals, such as mammals, birds, insects or fish, or plants, or other living creatures, can be, or are, or have been infected with LA or related agents.

Since LA has now been identified as the causal agent of MSD, it is possible to make a vaccine to protect pigs against this disease. Such a vaccine can simply be made by growing LA in pig lung macrophage cultures, or in other cell systems in which LA grows. LA can then be purified or not, and killed by established techniques, such as inactivation with formaline or ultra-violet light. The inactivated LA can then be combined with adjuvantia, such as Freund's adjuvans or aluminum hydroxide or others, and this composition can then be injected in pigs.

Dead vaccines can also be made with LA protein preparations derived from LA infected cultures, or derived from cell systems expressing specifically LA protein through DNA recombinant techniques. Such subunits of LA would then be treated as above, and this would result in a subunit vaccine.

Vaccines using even smaller components of LA, such as polypeptides, peptides, or peptides mimicking antigenic components of LA are also feasible for use as dead vaccine.

Dead vaccines against MSD can also be made by recombinant DNA techniques through which the genome of LA, or parts thereof, is incorporated in vector systems such as vaccinia virus, herpesvirus, pseudorabies virus, adeno virus, baculo virus or other suitable vector systems that can so express LA antigen in appropriate cells systems. LA antigen from these systems can then be used to develop a vaccine as above, and pigs, vaccinated with such products would develop protective immune responses against LA.

Vaccines against MSD can also be based on live preparations of LA. Since only young piglets and pregnant sows seem to be seriously affected by infection with LA, it is possible to use unattenuated LA, grown in pig lung macrophages, as vaccine for older piglets, or breeding gilts. In this way sows can be protected against MSD before they get pregnant, which results in protection against abortions and stillbirth, and against congenital infections of piglets. Also the maternal antibody that these vaccinated sows give to their offspring would protect their offspring against the disease.

Attenuated vaccines (modified-live-vaccines) against MSD can be made by serially passaging LA in pig lung macrophages, in lung macrophages of other species, or in other cell systems, or in other animals, such as rabbits, until it has lost its pathogenicity.

Live vaccines against MSD can also be made by recombinant DNA techniques through which the genome of LA, or parts thereof, is incorporated in vector systems such as vaccinia virus, herpesvirus, pseudorabies virus, adeno virus or other suitable vector systems that can so express LA antigen. Pigs, vaccinated with such live vector systems would then develop protective immune responses against LA.

Lelystad agent itself would be specifically suited to use as a live vector system. Foreign genes could be inserted in the genome of LA and could be expressing the corresponding protein during the infection of the macrophages. This cell, which is an antigen presenting cell, would process the foreign antigen and present it to B-lymfocytes and T-lymfocytes which will respond with the appropriate immune respons.

Since LA seems to be very cell specific and possibly also very species specific, this vector system might be a very safe system, which does not harm other cells or species.

SHORT DESCRIPTION OF THE DRAWINGS

FIGS. 1a through 1g (SEQ ID NO: 1) shows the nucleotide sequence of the LV genome. The deduced amino acid sequence of the identified ORFs (SEQ ID NOS: 2-9) are shown. The methionines encoded by the (putative) ATG start sites are indicated in bold and putative N-glycosylation sites are underlined. Differences in the nucleotide and amino acid sequence, as identified by sequencing different cDNA clones, are shown. The nucleotide sequence of primer 25, which has been used in hybridization experiments (see FIG. 2 and section "results"), is underlined.

FIG. 2 shows the organization of the LV genome. The cDNA clones, which have been used for the determination of the nucleotide sequence, are indicated in the upper part of the figure. The parts of the clones, which were sequenced, are indicated in black. In the lower part of the figure the ORFs, identified in the nucleotide sequence, and the subgenomic set of mRNAs, encoding these ORFs, shown. The dashed lines in the ORFs represent alternative initiation sites (ATGs) of these ORFs. The leader sequence of the genomic and subgenomic RNAs is indicated by a solid box.

FIG. 3 shows the growth characteristics of LA:

empty squares--titre of cell-free virus;

solid squares--titre of cell-associated virus;

solid line--percentage cytopathic effect (CPE).

MATERIALS AND METHODS

Sample collection

Samples and pigs were collected from farms where a herd epizootic of MSD seemed to occur. Important criteria for selecting the farm as being affected with MSD were: sows that were off feed, the occurrence of stillbirth and abortion, weak offspring, respiratory disease and death among young piglets. Samples from four groups of pigs have been investigated:

(1) tissue samples and an oral swab from affected piglets from the field (table 1A),

(2) blood samples and oral swabs from affected sows in the field (tables 1B and 4),

(3) tissue samples, nasal swabs and blood samples collected from specific-pathogen-free (SPF) pigs experimentally infected by contact with affected sows from the field or

(4) tissue samples, nasal swabs and blood samples collected from specific-pathogen-free (SPF) pigs experimentally infected by inoculation with blood samples of affected sows from the field (tables 2 and 5).

Sample preparation

Samples for virus isolation were obtained from piglets and sows which on clinical grounds were suspected to have MSD, and from experimentally infected SPF pigs, sows and their piglets.

Tissue samples were cut on a cryostat microtome and sections were submitted for direct immunofluorescence testing (IFT) with conjugates directed against various pig pathogens.

10% Suspensions of tissues samples were prepared in Hank's BSS supplemented with antibiotics, and oral and nasal swabs were soaked in Hank's BSS supplemented with antibiotics. After one hour at room temperature, the suspensions were clarified for 10 min at 6000 g, and the supernatant was stored at -70° C. for further use. Leucocyte fractions were isolated from EDTA or heparin blood as described earlier (Wensvoort and Terpstra, 1988), and stored at -70° C. Plasma and serum for virus isolation was stored at -70° C.

Serum for serology was obtained from sows suspected to be in the acute phase of MSD, a paired serum was taken 3-9 weeks later. Furthermore, sera were taken from the experimentally infected SPF pigs at regular intervals and colostrum and serum was taken from experimentally infected sows and their piglets. Sera for serology were stored at -20° C.

Cells

Pig lung macrophages were obtained from lungs of 5-6 weeks old SPF pigs or from lungs of adult SPF sows from the Central Veterinary Institute's own herd. The lungs were washed five to eight times with phosphate buffered saline (PBS). Each aliquot of washing fluid was collected and centrifuged for 10 min at 300 g. The resulting cell pellet was washed again in PBS and resuspended in cell culture medium (160 ml medium 199, supplemented with 20 ml 2.95% tryptose phosphate, 20 ml foetal bovine serum (FBS), and 4.5 ml 1.4% sodium bicarbonate) to a concentration of 4×10⁷ cells/ml. The cell suspension was then slowly mixed with an equal volume of DMSO mix (6.7 ml of above medium, 1.3 ml FBS, 2 ml dimethylsulfoxide 97%), aliquoted in 2 ml ampoules and stored in liquid nitrogen.

Macrophages from one ampoule were prepared for cell culture by washing twice in Earle's MEM, and resuspended in 30 ml growth medium (Earle's MEM, supplemented with 10% FBS, 200 U/ml penicillin, 0.2 mg/ml streptomycine, 100 U/ml mycostatin, and 0.3 mg/ml glutamine). PK-15 cells (American Type Culture Collection, CCL33) and SK-6 cells (Kasza et al., 1972) were grown as described by Wensvoort et al. (1989). Secondary porcine kidney (PK2) cells were grown in Earle's MEM, supplemented with 10% FBS and the above antibiotics. All cells were grown in a cell culture cabinet at 37° C. and 5% CO₂.

Virus isolation procedures.

Virus isolation was performed according to established techniques using PK2, PK-15 and SK-6 cells, and pig lung macrophages. The former three cells were grown in 25 ml flasks (Greiner), and inoculated with the test sample when monolayers had reached 70-80% confluency. Macrophages were seeded in 100 μl aliquots in 96-well microtiter plates (Greiner) or in larger volumes in appropriate flasks, and inoculated with the test sample within one hour after seeding. The cultures were observed daily for cytopathic effects (CPE), and frozen at -70° C. when 50-70% CPE was reached or after five to ten days of culture. Further passages were made with freeze-thawed material of passage level 1 and 2 or higher. Some samples were also inoculated into nine to twelve day old embryonated hen eggs. Allantoic fluid was subinoculated two times using an incubation interval of three days and the harvest of the third passage was examined by haemagglutination at 4° C. using chicken red blood cells, and by an ELISA specifically detecting nucleoprotein of influenza A viruses (De Boer et al., 1990).

Serology

Sera were tested in haemagglutinating inhibition tests (HAI) to study the development of antibody against haemagglutinating encephalitis virus (HEV), and swine influenza viruses H1N1 and H3N2 according to the protocol of Masurel (1976). Starting dilutions of the sera in HAI were 1:9, after which the sera were diluted twofold.

Sera were tested in established enzyme-linked immunosorbent assays (ELISA) for antibodies against the glycoprotein gI of pseudorabies virus (PRV; Van Oirschot et al., 1988), porcine parvo virus (PPV; Westenbrink et al., 1986), bovine viral diarrhoea virus (BVDV; Westenbrink et al., 1986), and hog cholera virus (HCV; Wensvoort et al., 1988). Starting dilutions in the ELISA's were 1.5, after which the sera were diluted twofold.

Sera were tested for neutralizing antibodies against 30-300 TCID₅₀ of encephalomyocarditis viruses (EMCV), porcine enteroviruses (PEV), and Lelystad agent (LA) according to the protocol of Terpstra (1978). Starting dilutions of the sera in the serum neutralization tests (SNT) were 1:5, after which the sera were diluted twofold.

Sera were tested for binding with LA in an immunoperoxidase-monolayer assay (IPMA). Lelystad agent (LA; code: CDI-NL-2.91) was seeded in microtiter plates by adding 50 ml growth medium containing 100 TCID₅₀ LA to the wells of a microtiter plate containing freshly seeded lung macrophages. The cells were grown for two days and then fixed as described (Wensvoort, 1986). The test sera were diluted 1:10 in 0.15M NaCl, 0.05% Tween 80, 4% horse serum, or diluted further in fourfold steps, added to the wells and then incubated for one hour at 37° C. Sheep-anti-pig immunoglobulins (Ig) conjugated to horse radish peroxidase (HRPO, DAKO) were diluted in the same buffer and used in a second incubation for one hour at 37° C., after which the plates were stained as described (Wensvoort et al., 1986). An intense red staining of the cytoplasm of infected macrophages indicated binding of the sera to LA.

Virus identification procedures

The identity of cytopathic isolates was studied by determining the buoyant density in CsCl, by estimating particle size in negatively stained preparations through electron microscopy, by determining the sensitivity of the isolate to chloroform and by neutralizing the CPE of the isolate with sera with known specificity (Table 3). Whenever an isolate was specifically neutralized by a serum directed against a known virus, the isolate was considered to be a representative of this known virus.

Isolates that showed CPE on macrophage cultures were also studied by staining in IPMA with postinfection sera of pigs c 829 or b 822. The isolates were reinoculated on macrophage cultures and fixed at day 2 after inoculation before the isolate showed CPE. Whenever an isolate showed reactivity in IPMA with the postinfection sera of pigs c 829 or b 822, the isolate was considered to be a representative of the Lelystad agent. Representatives of the other isolates grown in macrophages or uninfected macrophages were also stained with these sera to check the specificity of the sera.

Further identification of Lelystad agent.

Lelystad agent was further studied by haemagglutination at 4° C. and 37° C. with chicken, guinea pig, pig, sheep, or human O red blood cells. SIV, subtype H3N2, was used as positive control in the haemagglutination studies.

The binding of pig antisera specifically directed against pseudorabies virus (PRV), transmissible gastroenteritis virus (TGE), porcine epidemic diarrhoea virus (PED), haemagglutinating encephalitis virus (HEV), African swine fever virus (ASFV), hog cholera virus (HCV) and swine influenza virus (SIV) type H1N1 and H3N2, of bovine antisera specifically directed against bovine herpes viruses type 1 and 4 (BHV 1 and 4), malignant catarrhal fever (MCF), parainfluenza virus 3 (PI3), bovine respiratory syncitial virus (BRSV) and bovine leukemia virus (BLV), and of avian antisera specifically directed against avian leukemia virus (ALV) and infectious bronchitis virus (IBV) was studied with species-Ig specific HRPO conjugates in an IPMA on LA infected and uninfected pig lung macrophages as described above.

We also tested in IPMA antisera of various species directed against mumps virus, Sendai virus, canine distemper virus, rinderpest virus, measles virus, pneumonia virus of mice, bovine respiratory syncytial virus, rabies virus, foamy virus, maedi-visna virus, bovine and murine leukemia virus, human, feline and simian immunodeficiency virus, lymphocytic choriomeningitis virus, feline infectious peritonitis virus, mouse hepatitis virus, Breda virus, Hantaan virus, Nairobi sheep disease virus, Eastern, Western and Venezuelan equine encephalomyelitis virus, rubella virus, equine arteritis virus, lactic dehydrogenase virus, yellow fever virus, tickborn encephalitis virus and hepatitis C virus.

LA was blindly passaged in PK2, PK-15, and SK-6 cells, and in embryonated hen eggs. After two passages, the material was inoculated again into pig lung macrophage cultures for reisolation of LA.

LA was titrated in pig lung macrophages prior to and after passing through a 0.2 micron filter (Schleicher and Schuell). The LA was detected in IPMA and by its CPE. Titres were calculated according to Reed and Muench (1938).

We further prepared pig antisera directed against LA. Two SPF pigs (21 and 23) were infected intranasally with 10⁵ TCID₅₀ of a fifth cell culture passage of LA. Two other SPF pigs (25 and 29) were infected intranasally with a fresh suspension of the lungs of an LA-infected SPF piglet containing 10⁵ TCID₅₀ LA. Blood samples were taken at 0, 14, 28, and 42 days postinfection (dpi).

We further grew LA in porcine alveolar macrophages to determine its growth pattern over time. Porcine alveolar macrophages were seeded in F25 flasks (Greiner), infected with LA with a multiplicity of infection of 0.01 TCID₅₀ per cell. At 8, 16, 24, 32, 40, 48, 56, and 64 h after infection, one flask was examined and the percentage of CPE in relation to a noninfected control culture was determined. The culture medium was then harvested and replaced with an equal volume of phosphate-buffered saline. The medium and the flask were stored at -70° C. After all cultures had been harvested, the LA titres were determined and expressed as log TCID₅₀ ml⁻¹.

The morphology of LA was studied by electronmicroscopy. LA was cultured as above. After 48 h, the cultures were freeze-thawed and centrifuged for 10 min at 6000× g. An amount of 30 ml supernatant was then mixed with 0.3 ml LA-specific pig serum and incubated for 1.5 h at 37° C. After centrifugation for 30 min at 125,000× g, the resulting pellet was suspended in 1% Seakem agarose ME in phosphate-buffered saline at 40° C. After coagulation, the agarose block was immersed in 0.8% glutaraldehyde and 0.8% osmiumtetroxide (Hirsch et al., 1968) in veronal/acetate buffer, pH 7.4 (230 mOsm/kg H₂ O), and fixed by microwave irradiation. This procedure was repeated once with fresh fixative. The sample was washed with water, immersed in 1% uranyl acetate, and stained by microwave irradiation. Throughout all steps, the sample was kept at 0° C. and the microwave (Samsung RE211D) was set at defrost for 5 min. Thin sections were prepared with standard techniques, stained with lead citrate (Venable et al., 1965), and examined in a Philips CM 10 electron microscope.

We further continued isolating LA from sera of pigs originating from cases of MSD. Serum samples originated from the Netherlands (field case the Netherlands 2), Germany (field cases Germany 1 and Germany 2; courtesy Drs. Berner, M unchen and Nienhoff, M unster), and the United States [experimental case United States 1 (experiment performed with ATCC VR-2332; courtesy Drs. Collins, St. Paul and Chladek, St. Joseph), and field cases United States 2 and United States 2; courtesy Drs. van Alstine, West Lafayette and Slife, Galesburg]. All samples were sent to the "Centraal Diergeneeskundig Instituut, Lelystad" for LA diagnosis. All samples were used for virus isolation on porcine alveolar macrophages as described. Cytophatic isolates were passaged three times and identified as LA by specific immunostaining with anti-LA post infection sera b 822 and c 829.

We also studied the antigenic relationships of isolates NL1 (the first LA isolate; code CDI-NL-2.91), NL2, GE1, GE2, US1, US2, and US3. The isolates were grown in macrophages as above and were tested in IPMA with a set of field sera and two sets of experimental sera. The sera were also tested in IPMA with uninfected macrophages.

The field sera were: Two sera positive for LV (TH-187 and TO-36) were selected from a set of LA-positive Dutch field sera. Twenty-two sera were selected from field sera sent from abroad to Lelystad for serological diagnosis. The sera originated from Germany (BE-352, BE-392 and NI-f2; courtesy Dr. Berner, M unchen and Dr. Nienhoff, M unster), the United Kingdom (PA-141615, PA-141617 and PA-142440; courtesy Dr. Paton, Weybridge), Belgium (PE-1960; courtesy Prof. Pensaert, Gent), France (EA-2975 and EA-2985; courtesy Dr. Albina, Ploufragan), the United States (SL-441, SL-451, AL-RP9577, AL-P10814/33, AL-4994A, AL-7525, JC-MN41, JC-MN44 and JC-MN45; courtesy Dr. Slife, Galesburg, Dr. van Alstine, West Lafayette, and Dr. Collins, St. Paul), and Canada (RB-16, RB-19, RB-22 and RB-23; courtesy Dr. Robinson, Quebec).

The experimental sera were: The above described set of sera of pigs 21, 23, 25, and 29, taken at dpi 0, 14, 28, and 42. A set of experimental sera (obtained by courtesy of Drs. Chladek, St. Joseph, and Collins, St. Paul) that originated from four six-month-old gilts that were challenged intranasally with 10⁵.1 TCID₅₀ of the isolate ATCC VR-2332. Bloodsamples were taken from gilt 2B at 0, 20, 36, and 63 dpi; from gilt 9G at 0, 30, 44, and 68 dpi; from gilt 16W at 0, 25, 40, and 64 dpi; and from gilt 16Y at 0, 36, and 64 dpi.

To study by radio-immunoprecipitation assay (RIP; de Mazancourt et al., 1986) the proteins of LA in infected porcine alveolar macrophages, we grew LA-infected and uninfected macrophages for 16 hours in the presence of labeling medium containing ³⁵ S-Cysteine. Then the labeled cells were precipitated according to standard methods with 42 dpi post-infection sera of pig b 822 and pig 23 and with serum MN8 which was obtained 26 days after infecting a sow with the isolate ATCC VR-2332 (courtesy Dr. Collins, St. Paul). The precipitated proteins were analysed by electrophoresis in a 12% SDS-PAGE gel and visualized by fluorography.

To characterize the genome of LA, we extracted nuclear DNA and cytoplasmatic RNA from macrophage cultures that were infected with LA and grown for 24 h or were left uninfected. The cell culture medium was discarded, and the cells were washed twice with phosphate-buffered saline. DNA was extracted as described (Strauss, 1987). The cytoplasmic RNA was extracted as described (Favaloro et al., 1980), purified by centrifugation through a 5.7M CsCl cushion (Setzer et al., 1980), treated with RNase-free DNase (Pharmacia), and analyzed in an 0.8% neutral agarose gel (Moormann and Hulst, 1988).

Cloning and Sequencing

To clone LV RNA, intracellular RNA of LV-infected porcine lung alveolar macrophages (10 μg) was incubated with 10 mM methylmercury hydroxide for 10 minutes at room temperature. The denatured RNA was incubated at 42° C. with 50 mM Tris-HCl, pH 7.8, 10 mM MgCl₂, 70 mM KCl, 0.5 mM DATP, dCTP, dGTP and dTTP, 0.6 μg calf thymus oligonucleotide primers pd(N) 6 (Pharmacia) and 300 units of Moloney murine leukaemia virus reverse transcriptase (Bethesda Research Laboratories) in a total volume of 100 μl. 20 mM EDTA was added after 1 hr; the reaction mixture was then extracted with phenol/chloroform, passed through a Sephadex G50 column and precipitated with ethanol.

For synthesis of the second cDNA strand, DNA polymerase I (Boehringer) and RNase H (Pharmacia) were used (G ubler and Hoffman, 1983). To generate blunt ends at the termini, double-stranded cDNA was incubated with T4 DNA polymerase (Pharmacia) in a reaction mixture which contained 0.05 mM deoxynucleotide-triphosphates. Subsequently, cDNA was fractionated in a 0.8% neutral agarose gel (Moormann and Hulst, 1988). Fragments of 1 to 4 kb were electroeluted, ligated into the SmaI site of pGEM-4Z (Promega), and used for transformation of Escherichia coli strain DH5α (Hanahan, 1985). Colony filters were hybridized with a ³² P-labelled single-stranded cDNA probe. The probe was reverse transcribed from LV RNA which had been fractionated in a neutral agarose gel (Moormann and Hulst, 1988). Before use the single stranded DNA probe was incubated with cytoplasmic RNA from mock-infected lung alveolar macrophages.

The relationship between LV cDNA clones was determined by restriction enzyme analysis and by hybridization of Southern blots of the digested DNA with nick-translated cDNA probes (Sambrook et al., 1989).

To obtain the 3' end of the viral genome, we constructed a second cDNA library, using oligo (dT)₁₂₋₁₈ and a 3' LV specific oligonucleotide that was complementary to the minus-strand viral genome as a primer in the first-strand reaction. The reaction conditions for first- and second-strand synthesis were identical to those described above. This library was screened with virus-specific 3' end oligonucleotide probes.

Most part (>95%) of the cDNA sequence was determined with an Automated Laser Fluorescent A.L.F.™ sequencer from Pharmacia LKB. Fluorescent oligonucleotide primer directed sequencing was performed on double-stranded DNA using the AutoRead™ Sequencing Kit (Pharmacia) essentially according to procedures C and D described in the Autoread™ Sequencing Kit protocol. Fluorescent primers were prepared with FluorePrime™ (Pharamacia). The remaining part of the sequence was determined via double-stranded DNA sequencing using oligonucleotide primers in conjunction with a T7 polymerase based sequencing kit (Pharmacia) and α-³² S-dATP (Amersham). Sequence data were analysed using the sequence analysis programs PCGENE (Intelligenetics, Inc, Mountain View, USA) and FASTA (Pearson and Lipman, 1988).

Experimental reproduction of MSD.

Fourteen conventionally reared pregnant sows that were pregnant for 10-11 weeks were tested for antibody against LA in the IPMA. All were negative. Then two groups of four sows were formed and brought to the CVI. At week 12 of gestation, these sows were inoculated intranasally with 2 ml LA (passage level 3, titre 10⁴.8 TCID₅₀ /ml). Serum and EDTA blood samples were taken at day 10 after inoculation. Food intake, rectal temperature, and other clinical symptoms were observed daily. At farrowing, the data of birth and the number of dead and living piglets per sow were recorded, and samples were taken for virus isolation and serology.

RESULTS

Immunofluorescence

Tissue sections of pigs with MSD were stained in an IFT with FITC-conjugates directed against African swine fever virus, hog cholera virus, pseudorabies virus, porcine parvo virus, porcine influenza virus, encephalomyocarditis virus and Chlamydia psittaci. The sections were stained, examined by fluorescent microscopy and all were found negative.

Virus isolation from piglets from MSD affected farms.

Cytopathic isolates were detected in macrophage cultures inoculated with tissue samples of MSD affected, two-to-ten day old piglets. Sixteen out of 19 piglets originating from five different farms were positive (Table 1A). These isolates all reacted in IPMA with the post-infection serum of pig c 829, whereas non-inoculated control cultures did not react. The isolates therefore were representatives of LA. One time a cytopathic isolate was detected in an SK-6 cell culture inoculated with a suspension of an oral swab from a piglet from a sixth farm (farm VE) (Table 1A). This isolate showed characteristics of the picorna viridae and was neutralized by serum specific for PEV 2, therefore the isolate was identified as PEV 2 (Table 3). PK2, PK-15 cells and hen eggs inoculated with samples from this group remained negative throughout.

Virus isolation from sows from MSD affected farms.

Cytopathic isolates were detected in macrophage cultures inoculated with samples of MSD affected sows. 41 out of 63 sows originating from 11 farms were positive (Table 1B). These isolates all reacted in IPMA with the post-infection serum of pig b 822 and were therefore representatives of LA. On one occasion a cytopathic isolate was detected in a PK2 cell culture inoculated with a suspension of a leucocyte fraction of a sow from farm HU (Table 1B). This isolate showed characteristics of the picorna viridae and was neutralized by serum specific for EMCV, therefore the isolate was identified as EMCV (Table 3). SK-6, PK-15 cells and hen eggs inoculated with samples from this group remained negative.

Virus isolation from SPF pigs kept in contact with MSD affected sows.

Cytopathic isolated were detected in macrophage cultures inoculated with samples of SPF pigs kept in contact with MSD affected sows. Four of the 12 pigs were positive (Table 2). These isolates all reacted in IPMA with the post-infection serum of pig c 829 and of pig b 822 and were therefore representatives of LA. Cytopathic isolates were also detected in Pk2, PK-15 and SK-6 cell cultures inoculated with samples of these isolates were all neutralized by serum directed against PEV 7. One of these seven isolates was studied further and other characteristics also identified the isolate as PEV 7 (Table 3).

Virus isolation from SPF pigs inoculated with blood of MSD affected sows.

Cytopathic isolates were detected in macrophage cultures inoculated with samples of SPF pigs inoculated with blood of MSD affected sows. Two out of the eight pigs were positive (Table 2). These isolates all reacted in IPMA with the post-infection serum of pig c 829 and of pig b 822 and were therefore representatives of LA. PK2, SK-6 and PK-15 cells inoculated with samples from this group remained negative.

Summarizing, four groups of pigs were tested for the presence of agents that could be associated with mystery swine disease (MSD).

In group one, MSD affected piglets, the Lelystad agent (LA) was isolated from 16 out of 20 piglets; one time PEV 2 was isolated.

In group two, MSD affected sows, the Lelystad agent was isolated from 41 out of 63 sows; one time EMCV was isolated. Furthermore, 123 out of 165 MSD affected sows seroconverted to the Lelystad agent, as tested in the IPMA. Such massive seroconversion was not demonstrated against any of the other viral pathogens tested.

In group three, SPF pigs inoculated with blood of MSD affected sows, the LA was isolated from two pigs. All eight pigs seroconverted to LA.

Serology of sows from MSD affected farms.

Paired sera from sows affected with MSD were tested against a variety of viral pathogens and against the isolates obtained during this study (Table 4). An overwhelming antibody response directed against LA was measured in the IPMA (75% of the sows seroconverted, in 23 out of the 26 farms seroconversion was found), whereas with none of the other viral pathogens a clear pattern of seroconversion was found. Neutralizing antibody directed against LA was out detected. Serology of SPF pigs kept in contact with MSD affected sows.

All eight SPF pigs showed an antibody response in the IPMA against LA (Table 5). None of these sera were positive in the IPMA performed on uninfected macrophages. None of these sera were positive in the SNT of LA. The sera taken two weeks after contact had all high neutralizing antibody titres (>1280) against PEV 7, whereas the pre-infection sera were negative (>10), indicating that all pigs had also been infected with PEV 7.

Serology of SPF pigs inoculated with blood of MSD affected sows.

All eight SPF pigs showed an antibody response in the IPMA against LA (Table 5). None of these sera were positive in the IPMA performed on uninfected macrophages. None of these sera were positive in the SNT for LA. The pre- and two weeks post-inoculation sera were negative (<10) against PEV 7.

Further identification of Lelystad agent.

LA did not haemagglutinate with chicken, guinea pig, pig, sheep, or human O red blood cells.

LA did not react in IPMA with sera directed against PRV, TGE, PED, ASFV, etc.

After two blind passages, LA did not grow in PK2, PK-15, or SK-6 cells, or in embryonated hen eggs, inoculated through the allantoic route.

LA was still infectious after it was filtered through a 0.2 micro filter, titres before and after filtration were 10⁵.05 and 10⁵.3 TCID₅₀ as detected by IPMA.

Growth curve of LA (see FIG. 3). Maximum titres of cell-free virus were approximately 10⁵.5 TCID₅₀ ml⁻¹ from 34-48 h after inoculation. After that time the macrophages were killed by the cytopathic effect of LA.

Electronmicroscopy. Clusters of spherical LA particles were found. The particles measured 45-55 nm in diameter and contained a 30-35 nm nucleocapsid that was surrounded by a lipid bilayer membrane. LA particles were not found in infected cultures that were treated with negative serum or in negative control preparations.

Isolates from the Netherlands, Germany, and the United States. All seven isolates were isolated in porcine alveolar macrophages and passaged three to five times. All isolates caused a cytopathic effect in macrophage and could be specifically immunostained with anti-LA sera b 822 and the 42 dpi serum 23. The isolates were named NL2, GE1, GE2, US1, US2, and US3.

Antigenic relationships of isolates NL1, NL2, GE1, GE2, US1, US2, and US3. None of the field sera reacted in IPMA with uninfected macrophages but all sera contained antibodies directed against one or more of the seven isolates (Table 7). None of the experimental sera reacted in IPMA with uninfected macrophages, and none of the 0 dpi experimental sera reacted with any of the seven isolates in IPMA (Table 8). All seven LA isolates reacted with all or most of the sera from the set of experimental sera of pigs 21, 23, 25, and 29, taken after 0 dpi. Only the isolates US1, US2, and US3 reacted with all or most of the sera from the set of experimental sera of gilts 2B, 9G, 16W, and 16Y, taken after 0 dpi.

Radioimmunoprecipitation studies. Seven LA-specific proteins were detected in LA-infected macrophages but not in uninfected macrophages precipitated with the 42 dpi sera of pigs b 822 and 23. The proteins had estimated molecular weights of 65, 39, 35, 26, 19, 16, and 15 kilodalton. Only two of these LA-specific proteins, of 16 and 15 kilodalton, were also precipitated by the 26 dpi serum MN8.

Sequence and oraganization of the genome of LV

The nature of the genome of LV was determined by analyzing DNA and RNA from infected porcine lung alveolar macrophages. No LV-specific DNA was detected. However, we did detect LV-specific RNA. In a 0.8% neutral agarose gel LV RNA migrated slightly slower than a preparation of hog cholera virus RNA of 12.3 kb (Moormann et al., 1990) did. Although no accurate size determination can be performed in neutral agarose gels, it was estimated that the LV-specific RNA is about 14.5 to 15.5 kb in length.

To determine the complexity of the LV-specific RNAs in infected cells and to establish the nucleotide sequence of the genome of LV, we prepared cDNA from RNA of LV-infected porcine lung alveolar macrophages and selected and mapped LV-specific cDNA clones as described under Materials and Methods. The specificity of the cDNA clones was reconfirmed by hybridizing specific clones, located throughout the overlapping cDNA sequence, to Northern blots carrying RNA of LV-infected and uninfected macrophages. Remarkably, some of the cDNA clones hybridized with the 14.5 to 15.5 kb RNA detected in infected macrophages only, whereas others hybridized with the 14.5 to 15.5 kb RNA as well as with a panel of 4 or 5 RNAs of lower molecular weight (estimated size, 1 to 4 kb). The latter clones were all clustered at one end of the cDNA map and covered about 4 kb of DNA. These data suggested that the genome organization of LV may be similar to that of coronaviridae (Spaan et al., 1988), Berne virus (BEV; Snijder et al., 1990b), a torovirus, and EAV (de Vries et al., 1990), i.e. besides a genomic RNA there are subgenomic mRNAs which form a nested set which is located at the 3' end of the genome. This assumption was confirmed when sequences of the cDNA clones became available and specific primers could be selected to probe the blots with. A compilation of the hybridization data obtained with cDNA clones and specific primers, which were hybridized to Northern blots carrying the RNA of LV-infected and uninfected macrophages, is shown in FIG. 2. Clones 12 and 20 which are located in the 5' part and the centre of the sequence respectively hybridize to the 14.5 to 15.5 kb genomic RNA detected in LV-infected cells only. Clones 41 and 39, however, recognize the 14.5 to 15.5 kb genomic RNA and a set of 4 and 5 RNAs of lower molecular weight, respectively. The most instructive and conclusive hybridization pattern, however, was obtained with primer 25, which is located at the ultimate 5' end in the LV sequence (compare FIG. 1). Primer 25 hybridized to a panel of 7 RNAs, with an estimated molecular weight ranging in size from 0.7 to 3.3 kb (subgenomic mRNAs), as well as the genomic RNA. The most likely explanation for the hybridization pattern of primer 25 is that 5' end genomic sequences, the length of which is yet unknown, fuse with the body of the mRNAs which are transcribed from the 3' end of the genome. In fact, the hybridization pattern obtained with primer 25 suggests that 5' end genomic sequences function as a so called "leader sequence" in subgenomic mRNAs. Such a transcription pattern is a hallmark of replication of coronaviridae (Spaan et al., 1988), and of EAV (de Vries et al., 1990).

The only remarkable discrepancy between LV and EAV which could be extracted from the above data is that the genome size of LV is about 2.5 kb larger than that of EAV.

The consensus nucleotide sequence of overlapping cDNA clones is shown in FIG. 1 (SEQ ID NO: 1). The length of the sequence is 15,088 basepairs, which is in good agreement with the estimated size of the genomic LV RNA.

Since the LV cDNA library was made by random priming of the reverse transcriptase reaction with calf thymus pd(N) 6 primers, no cDNA clones were obtained which started with a poly-A stretch at their 3' end. To clone the 3' end of the viral genome, we constructed a second cDNA library, using oligo (dT) and primer 39U183R in the reverse transcriptase reaction. Primer 39U183R is complementary to LV minus-strand RNA, which is likely present in a preparation of RNA isolated from LV-infected cells. This library was screened with virus-specific probes (nick-translated cDNA clone 119 and oligonucleotide 119R64R), resulting in the isolation of five additional cDNA clones (e.g., cDNA clone 151, FIG. 2). Sequencing of these cDNA clones revealed that LV contains a 3' poly(A) tail. The length of the poly(A) tail varied between the various cDNA clones, but its maximum length was twenty nucleotides. Besides clone 25 and 155 (FIG. 2), four additional cDNA clones were isolated at the 5' end of the genome, which were only two to three nucleotides shorter than the ultimate 5' nucleotide shown in FIG. 1 (SEQ ID NO: 1). Given this finding and given the way cDNA was synthesized, we assume to be very close to the 5' end of the sequence of LV genomic RNA.

Nearly 75% of the genomic sequence of LV encodes ORF 1A and ORF 1A probably initiates at the first AUG (nucleotide position 212, FIG. 1) encountered in the LV sequence. The C-terminus of ORF 1A overlaps the putative N-terminus of ORF 1B over a small distance of 16 nucleotides. It thus seems that translation of ORF 1B proceeds via ribosomal frameshifting, a hallmark of the mode of translation of the polymerase or replicase gene of coronaviruses (Boursnell et al. 1987; Bredenbeek et al. 1990) and the torovirus BEV (Snijder et al., 1990a). The characteristic RNA pseudoknot structure which is predicted to be formed at the site of the ribosomal frameshifting is also found at this location in the sequence of LV (results not shown).

ORF 1B encodes an amino acid sequence (SEQ ID NO: 3) or nearly 1400 residues which is much smaller than ORF 1B of the coronaviruses MHV and IBV (about 3,700 amino acid residues; Bredenbeek et al., 1990; Boursnell et al., 1987) and BEV (about 2,300 amino acid residues; Snijder et al., 1990a). Characteristic features of the ORF 1B product (SEQ ID NO: 3) or members of the superfamily of coronaviridae like the replicase motif and the Zinc finger domain can also be found in ORF 1B of LV (results not shown).

Whereas ORF 1A and ORF 1B encode the viral polymerase (SEQ ID NO: 2) and (SEQ ID NO: 3) and therefore are considered to encode a non-structural viral protein, ORFs 2 to 7 are believed to encoded structural viral proteins (SEQ ID NOS: 4-9).

The products of ORFs 2 to 6 (SEQ ID NOS: 4-8) all show features reminiscent of membrane (envelope) associated proteins. ORF 2 encodes a protein (SEQ ID NO: 4) of 249 amino acids containing two predicted N-linked glycosylation sites (Table 9). At the N-terminus a hydrophobic sequence, which may function as a so called signal sequence, is identified. The C-terminus also ends with a hydrophobic sequence which in this case may function as a transmembrane region which anchors the ORF 2 product (SEQ ID NO: 4) in the viral envelope membrane.

ORF 3 may initiate at the AUG starting at nucleotide position 12394 or at the AUG starting at nucleotide position 12556 and then encodes proteins (SEQ ID NO: 5) of 265 and 211 amino acids respectively. The protein of 265 residues contains seven putative N-linked glycosylation sites, whereas the protein of 211 residues contains four (Table 9). At the N-terminus of the protein (SEQ ID NO: 5) of 265 residues a hydrophobic sequence is identified.

Judged by hydrophobicity analysis, the topology of the protein encoded by ORF 4 (SEQ ID NO: 6) is similar to that encoded by ORF 2 (SEQ ID NO: 4) if the product of ORF 4 (SEQ ID NO: 6) initiates at the AUG starting at nucleotide position 12936. However, ORF 4 may also initiate at two other AUG codons (compare FIGS. 1 and 2) starting at positions 12981 and 13068 in the sequence respectively. Up to now it is unclear which startcodon is used. Depending on the startcodon used, ORF 4 may encode proteins (SEQ ID NO: 6) of 183 amino acids containing four putative N-linked glycosylation sites, of 168 amino acids containing four putative N-linked glycosylation sites, or of 139 amino acids containing three putative N-linked glycosylation sites (Tables 9).

ORF 5 is predicted to encode a protein (SEQ ID NO: 7) of 201 amino acids having two putative N-linked glycosylation sites (Table 9). A characteristic feature of the ORF 5 product (SEQ ID NO: 7) is the internal hydrophobic sequence between amino acid 108 to amino acid 132.

Analysis for membrane spanning segments and hydrophilicity of the product of ORF 6 (SEQ ID NO: 8) shows that it contains three transmembrane spanning segments in the N-terminal 90 amino acids of its sequence. This remarkable feature is also a characteristic of the small envelope glycoprotein M or E1 of several coronaviruses e.g. Infectious Bronchitis Virus (IBV; Boursnell et al., 1984)_and Mouse Hepatitis Virus (MHV; Rottier et al., 1986). It is therefore predicted that the protein encoded by ORF 6 (SEQ ID NO: 8) has a membrane topology analogous to that of the M of E1 protein of coronaviruses (Rottier et al., 1986). A second characteristic of the M or E1 protein is a so called surface helix which is located immediately adjacent to the presumed third transmembrane region. This sequence of about 25 amino acids which is very well conserved among coronaviruses is also recognized, although much more degenerate, in LV. Yet we predict the product of LV ORF 6 (SEQ ID NO: 8) to have an analogous membrane associated function as the coronavirus M or E1 protein. Furthermore, the protein encoded by ORF (SEQ ID NO: 8) showed a strong similarity (53% identical amino acids) with VpX (Godeny et al., 1990) of LDV.

The protein encoded by ORF 7 (SEQ ID NO: 9) has a length of 128 amino acid residues (Table 9) which is 13 amino acids longer than Vp1 of LDV (Godeny et al., 1990). Yet a significant similarity (43% identical amino acids) was observed between the protein encoded by ORF 7 (SEQ ID NO: 9) and Vp1. Another shared characteristic between the product of ORF 7 and Vp1 is the high concentration of basis residues (Arg, Lys and His) in the N-terminal half of the protein. Up to amino acid 55 the LV sequence contains 26% Arg, Lys and His. This finding is fully in line with the proposed function of the ORF 7 product (SEQ ID NO: 9) or Vp1 (Godeny et al., 1990), namely encapsidation of the viral genomic RNA. On the basis of above data, we propose the LV ORF 7 product (SEQ ID NO: 9) to be the nucleocapsid protein N of the virus.

A schematic representation of the organization of the LV genome is shown in FIG. 2. The map of overlapping clones used to determine the sequence of LV is shown in the top panel. A linear compilation of this map indicating the 5' and 3' end of the nucleotide sequence of LV, shown in FIG. 1 (SEQ ID NO: 1), including a division in kilobases is shown below the map of cDNA clones and allows the positioning of these clones in the sequence. The position of the ORFs identified in the LV genome is indicated below the linear map of the LV sequence. The bottom panel shows the nested set of subgenomic mRNAs and the position of these RNAs relative to the LV sequence.

In line with the translation strategy of coronavirus, torovirus and arterivirus subgenomic mRNAs it is predicted that ORFs 1 to 6 are translated from the unique 5' end of their genomic or mRNAs. This unique part of the mRNAs is considered to be that part of the RNA that is obtained when a lower molecular weight RNA is "subtracted" from the higher molecular weight RNA which is next in line. Although RNA 7 forms the 3' end of all the other genomic and subgenomic RNAs, and thus does not have a unique region, it is believed that ORF 7 is only translated from this smallest sized mRNA. The "leader sequence" at the 5' end of the subgenomic RNAs is indicated with a solid box. The length of this sequence is about 200 bases, but the precise site of fusion with the body of the genomic RNAs still has to be determined.

Experimental reproduction of MSD

Eight pregnant sows were inoculated with LA and clinical signs of MSD such as inappetance and reproductive losses were reproduced in these sows. From day four to day 10-12 post-inoculation (p.i.), all sows showed a reluctance to eat. None of the sows had elevated body temperatures. Two sows had bluish ears at day 9 and 10 p.i. In Table 6 the day of birth and the number of living and dead piglets per sow is given. LA was isolated from 13 of the born piglets.

                  TABLE 1                                                          ______________________________________                                         Description and results of virus isolation of field samples.                   ______________________________________                                         A Samples of piglets suspected of infection with MSD.                                 number   age                                                            farm   of pigs  days   material used results*                                  ______________________________________                                         RB     5        2      lung, tonsil, and brains                                                                     5 × LA                              DV     4        3      lung, brains, 3 × LA                                                     pools of kidney, spleen                                 TH     3        3-5    lung, pools of kidney,                                                                       3 × LA                                                     tonsil                                                  DO     3        10     lung, tonsil  2 × LA                              ZA     4        1      lung, tonsil  3 × LA                              VE     1        ?      oral swab     1 × PEV 2                           TOTAL  20                            16 × LA,                                                                 1 × PEV 2                           ______________________________________                                         B Samples of sows suspected of infection with MSD.                                    number                                                                  farm   of sows  material used  results                                         ______________________________________                                         TH     2        plasma and leucocytes                                                                         1 × LA                                    HU     5        plasma and leucocytes                                                                         2 × LA,                                                                  1 × EMCV                                  TS     10       plasma and leucocytes                                                                         6 × LA                                    HK     5        plasma and leucocytes                                                                         2 × LA                                    LA     6        plasma and leucocytes                                                                         2 × LA                                    VL     6        serum and leucocytes                                                                          5 × LA                                    TA     15       serum          11 × LA                                   LO     4        plasma and leucocytes                                                                         2 × LA                                    JA     8        plasma and leucocytes                                                                         8 × LA                                    VD     1        plasma and leucocytes                                                                         1 × LA                                    VW     1        serum          1 × LA                                    TOTAL  63                      41 × LA,                                                                 1 × EMCV                                  ______________________________________                                          *Results are given as the number of pigs from which the isolation was          made. Sometimes the isolate was detected in more then one sample per pig.      LA = Lelystad agent                                                            PEV 2 = porcine entero virus type 2                                            EMCV = encephalomyocarditis virus                                        

                  TABLE 2                                                          ______________________________________                                         Description and results of virus isolation of samples of pigs                  with experimentally induced infections.                                        sow     pig@    material used results*                                         ______________________________________                                         A (LO) #                                                                               c 835   lung, tonsil  2 × LA                                             c 836   nasal swabs   2 × PEV 7                                          c 837   nasal swabs                                                    B (JA)  c 825   lung, tonsil                                                           c 821   nasal swabs   1 × PEV 7                                          c 823   nasal swabs   4 × PEV 7                                  C (JA)  c 833   lung tonsil   1 × LA, 1 × PEV 7                            c 832   nasal swabs   2 × PEV 7                                          c 829   nasal swabs, plasma                                                                          3 × LA, 2 × PEV 7                                    and leucocytes                                                 D (VD)  c 816   lung, tonsil                                                           c 813   nasal swabs   1 × LA                                             c 815   nasal swabs   1 × PEV 7                                  TOTAL isolates from contact pigs                                                                     7 × LA, 13 × PEV 7                           ______________________________________                                         A       b 809   nasal swabs                                                            b 817   nasal swabs                                                    B       b 818   nasal swabs, plasma                                                                          1 × LA                                                     and leucocytes                                                         b 820   nasal swabs                                                    C       b 822   nasal swabs                                                            b 826   nasal swabs                                                    D       b 830   nasal swabs   1 × LA                                             b 834   nasal swabs                                                    TOTAL isolates from blood                                                                            2 × LA                                             inoculated pigs                                                                ______________________________________                                          @ SPF pigs were either kept in contact (c) with a sow suspected to be          infected with MSD, or were given 10 ml EDTA blood (b) of that sow              intramuscularly at day 0 of the experiment. Groups of one sow and three        SPF pigs (c) were kept in one pen, and all four of these groups were           housed in one stable. At day 6, one SPF pig in each group was killed and       tonsil and lungs were used for virus isolation. The four groups of SPF         pigs inoculated with blood (b) were housed in four other pens in a             separate stable. Nasal swabs of the SPF pigs were taken at day 2, 5, 7 an      9 of the experiment, and EDTA blood for virus isolation from plasma and        leucocytes was taken whenever a pig had fever.                                 *Results are given as number of isolates per pig.                              LA = Lelystad agent                                                            PEV 7 = porcine entero virus type 7                                            # In brackets the initials of the farm of origin of the sow are given.   

                  TABLE 3                                                          ______________________________________                                         Identification of viral isolates                                                       buoyant.sup.1                                                                           particle.sup.2   neutralized by.sup.4                         origin and                                                                             density  size in  sens.sup.3. to                                                                         serum directed                               cell culture                                                                           in CsCl  FM (nm)  chloroform                                                                             against (titre)                              ______________________________________                                         leucocytes                                                                             1.33 g/ml                                                                               28-30    not sens.                                                                              EMCV ( 1280)                                 sow farm                                                                       HU PK15,                                                                       PK2, SK6                                                                       oral swab                                                                              ND       28-30    not sens.                                                                              PEV 2 (>1280)                                piglet farm                                                                    VE SK6                                                                         nasal   ND       28-30    not sens.                                                                              PEV 7 (>1280)                                swabs,                                                                         tonsil                                                                         SPF pigs                                                                       CVI                                                                            PK-15,                                                                         PK2, SK6                                                                       various 1.19 g/ml                                                                               pleomorf sens.   none (all <5)                                samples                                                                        various                                                                        farms                                                                          pig                                                                            lung                                                                           macro-                                                                         phages                                                                         ______________________________________                                          .sup.1 Buoyant density in preformed lineair gradients of CsCl in PBS was       determined according to standard techniques (Brakke; 1967). Given is the       density where the peak of infectivity was found.                               .sup.2 Infected and noninfected cell cultures of the isolate under study       were freezethawed. Cell lysates were centrifuged for 30 min at 130,000 g,      the resulting pellet was negatively stained according to standard              techniques (Brenner and Horne; 1959), and studied with a Philips CM 10         electron microscope. Given is the size of particles that were present in       infected and not present in noninfected cultures.                              .sup.3 Sensitivity to chloroform was determined according to standard          techniques (Grist, Ross, and Bell; 1974).                                      .sup.4 Hundred to 300 TCID.sub.50 of isolates were mixed with varying          dilutions of specific antisera and grown in the appropriate cell system        until full CPE was observed. Sera with titres higher then 5 were retested      and sera which blocked with high titres the CPE were considered specific       for the isolate. The isolates not sensitive to chloroform were tested wit      sera specifically directed against porcine entero viruses (PEV) 1 to 11        (courtesy Dr. Knowles, Pirbright, UK), against encephalomyocarditis virus      (EMCV; courtesy Dr. Ahl, Tubingen, Germany), against porcine parvo virus,      and against swine vesicular disease.                                           The isolate (code: CDINL-2.91) sensitive to chloroform was tested with         antisera specifically directed against pseudorabies virus, bovine herpes       virus 1, bovine herpes virus 4, malignant catarrhal virus, bovine viral        diarrhoea virus, hog cholera virus, swine influenza virus H1N1 and H3N2,       parainfluenza 3 virus, bovine respiratory syncitial virus, transmissible       gastroenteritis virus, porcine epidemic diarrhoea virus, haemaglutinating      encephalitis virus, infectious bronchitis virus, bovine leukemia virus,        avian leukemia virus, maedivisna virus, and with the experimental sera         obtained from the SPFpigs (see Table 5).                                 

                                      TABLE 4                                      __________________________________________________________________________     Results of serology of paired field sera taken from sows                       suspected to have MSD. Sera were taken in the acute phase of                   the disease and 3-9 weeks later. Given is the number of sows                   which showed a fourfold or higher rise in titre/number of sows                 tested.                                                                        __________________________________________________________________________         Interval.sup.i                                                                      HAI            ELISA                                                  Farm                                                                               in weeks                                                                            HEV  H1N1 H3N2 PBV  PPV BVDV HCV                                      __________________________________________________________________________     TH  3    0/6  0/6  0/6  0/6  0/6 0/5  0/6                                      RB  5     0/13                                                                                1/13                                                                                0/13                                                                               1/9  0/7 0/6  0/9                                      HU  4    0/5  0/5  3/5  0/5  0/5 0/5  0/5                                      TS  3     1/10                                                                                0/10                                                                                0/10                                                                                0/10                                                                                0/10                                                                              0/4   0/10                                    VL  3    0/5  0/5  0/5  0/5  1/5 0/5  0/5                                      JA  3     0/11                                                                                1/11                                                                                3/11                                                                                0/11                                                                                2/11                                                                               0/11                                                                                0/11                                    WE  4    1/6  1/6  1/6  3/7  3/7 0/7  0/7                                      GI  4    0/4  1/4  0/4  0/4  0/4 0/4  0/4                                      SE  5    0/8  0/8  0/8  0/8  0/6 0/3  0/8                                      KA  5    0/1  0/1  0/1  0/1  0/1 ND   0/1                                      HO  3    1/6  0/5  1/6  0/6  0/6 0/6  0/6                                      NY  4    0/5  1/5  1/5  0/3  0/4 0/2  0/4                                      JN  3     0/10                                                                                5/10                                                                                0/10                                                                                0/10                                                                                1/10                                                                               0/10                                                                                0/10                                    KO.sup.f                                                                           3     1/10                                                                                0/10                                                                                0/10                                                                                0/10                                                                                2/10                                                                               0/10                                                                                0/10                                    OE  9    ND   ND   ND   0/6  0/6 0/6  0/6                                      LO  6    ND   ND   ND   0/3  0/3 0/2  0/3                                      WI  4    ND   ND   ND   0/1  1/1 0/1  0/3                                      RR  3    ND   ND   ND   1/8  0/8 0/8  0/8                                      RY  4    ND   ND   ND   0/3  0/4 0/3  0/4                                      BE  5    ND   ND   ND    10   0/10                                                                               0/10                                                                                0/10                                    BU  3    ND   ND   ND   1/6  0/6 0/6  0/6                                      KR  3    ND   ND   ND   1/4  0/4 0/4  0/4                                      KW  5    ND   ND   ND    0/10                                                                                0/10                                                                               0/10                                                                                0/10                                    VR  5    ND   ND   ND   1/6  0/6 0/6  0/6                                      HU  4    ND   ND   ND   1/4  0/3 0/3  0/4                                      ME  3    ND   ND   ND   0/5  1/5 0/5  0/5                                      total negative.sup.n                                                                    19   41   29   97    16 140  165                                      total positive.sup.p                                                                    77   48   62   55   131  1    0                                       total sero-                                                                              4   10    9    9    11  0    0                                       converted.sup.s                                                                total tested                                                                            100  99   100  161  158 141  165                                      __________________________________________________________________________      The sera were tested in haemagglutinating inhibition (HAI) tests for the       detection of antibody against haemagglutinating encephalitis virus (HEV),      and swine influenza viruses H1N1 and H3N2, in enzymelinked-immuno sorbent      assays (ELISA) for the detection of antibody against the glycoprotein gI       of pseudorabies virus (PRV), against porcine parvo virus (PPV), bovine         viral diarrhoea virus (BVDV), and hog cholera virus (HCV).               

        Interval                                                                            SNT                          IPMA                                     Farm                                                                               in weeks                                                                            FMCV                                                                               FMCVi                                                                               PEV2                                                                               PEV2i                                                                              PEV7                                                                               PEV7i                                                                              LA  LA                                       __________________________________________________________________________     TH  3    0/6 0/6  0/5 0/5 0/6 0/5 0/6 6/6                                      RB  5    1/7 1/9  0/6 2/6 1/8 0/6  0/13                                                                              7/9                                      HU  4    ND  0/5  0/5 0/5 ND  0/5 0/5 3/5                                      TS  3     0/10                                                                               0/10                                                                               0/7 0/4  0/10                                                                              0/7 ND  10/10                                    VL  3    ND  ND   1/5 0/5 ND  0/5 ND  5/5                                      JA  3     0/11                                                                               0/11                                                                                0/11                                                                               0/11                                                                               1/11                                                                               2/11                                                                              0/5  8/11                                    WE  4    1/7 1/6  1/6 1/7 1/7 1/7 0/7 7/7                                      GI  4    0/4 0/4  0/4 0/4 0/4 0/4 0/4 4/4                                      SE  5    0/8 0/8  0/6 1/8 0/8 1/5 0/8 6/8                                      KA  5    0/1 0/1  0/1 0/1 0/1 0/1 0/1 0/1                                      HO  3    0/6 0/6  0/6 0/6 0/6 0/6 0/6 4/6                                      NY  4    0/4 0/4  0/2 0/2 0/4 0/3 0/4 4/4                                      JN  3     0/10                                                                               0/10                                                                                1/10                                                                              0/9  0/10                                                                               0/10                                                                               0/10                                                                               5/10                                    KO.sup.f                                                                           3     0/10                                                                               0/10                                                                                2/10                                                                               2/10                                                                               1/10                                                                               3/10                                                                              ND   8/10                                    OE  9    0/6 0/6  1/6 1/5 ND  1/6 ND  4/6                                      LO  6    0/3 0/3  0/3 0/3 0/3 0/3 ND  3/3                                      WI  4    ND  ND   0/1 0/1 ND  0/1 ND  0/3                                      RR  3    0/8 1/8  0/8 0/8 0/8 0/8 ND  8/8                                      RY  4    0/4 ND   0/4 0/1                                                      BE  5    ND  ND    0/10                                                                               0/10                                                                              ND   1/10                                                                              ND   0/10                                    BU  3    ND  ND   0/6 0/6 ND  0/6 ND  6/ 6                                     KR  3    ND  ND   0/4 0/4 ND  0/4 ND  1/4                                      KW  5    ND  ND    0/10                                                                               0/10                                                                              ND   1/10                                                                              ND  10/10                                    VR  5    ND  ND   0/6 1/6 ND  0/6 Nn  6/6                                      HU  4    ND  ND   0/3 0/4 ND  0/3 ND  3/4                                      ME  3    ND  ND   0/5 0/5 ND  0/5 ND  2/5                                      total neg..sup.n                                                                        15  29    0  0    2   1  69   15                                      total pos..sup.p                                                                        88  74   144 138 90  136  0   27                                      total sero-                                                                              2   3    6   8   4   10  0  123                                      converted.sup.s                                                                total tested                                                                            105 107  150 146 96  147 69  165                                      __________________________________________________________________________      The sera were tested in serum neutralization tests (SNT) for the detectio      of neutralizing antibody directed against encephalomyocarditis virus           (EMCV), the isolated (i) EMCV, porcine entero viruses (PEV) 2 and 7 and        the PEV isolates (i), and against the Lelystad agent (LA), and were teste      in an immunoperoxidase-monolayer-assay (IPMA) for the detection of             antibody directed against the Lelystad agent (LA).                             .sup.f fattening pigs. .sup.i time between sampling of the first and           second serum. .sup.n total number of pigs of which the first serum was         negative in the test under study, and of which the second serum was also       negative or showed a less then fourfold rise in titre. .sup.p total numbe      of pigs of which the first serum was fourfold rise in titre. .sup.s total      number of pigs of which the second serum had a fourfold or higher titre        then the first serum in the test under study. ND = not done.             

                  TABLE 5                                                          ______________________________________                                         Development of antibody directed against Lelystad agent as                     measured by IPMA.                                                              ______________________________________                                         A contact pigs                                                                 Weeks post contact:                                                                          serum titres in IPMA                                             Pig           0     2      3     4      5                                      ______________________________________                                         c 836         0      10    640   640    640                                    c 837         0      10    640   640    640                                    c 821         0     640    640   640    640                                    c 823         0     160    2560  640    640                                    c 829         0     160    640   10240  10240                                  c 832         0     160    640   640    2560                                   c 813         0     640    2560  2560   2560                                   c 815         0     160    640   640    640                                    ______________________________________                                         B blood inoculated pigs                                                                      serum titres in IPMA                                             Weeks post inoculation:                                                                      0     2      3     4      6                                      ______________________________________                                         b 809         0     640    2560  2560   2560                                   b 817         0     160    640   640    640                                    b 818         0     160    640   640    640                                    b 820         0     160    640   640    640                                    b 822         0     640    2560  2560   10240                                  b 826         0     640    640   640    10240                                  B 830         0     640    640   640    2560                                   B 834         0     160    640   2560   640                                    ______________________________________                                          See Table 2 for description of the experiment. All pigs were bled at           regular intervals and all sera were tested in an                               immunoperoxidase-monolayer-assay (IPMA) for the detection of antibody          directed against the Lelystad agent (LA).                                

                  TABLE 6                                                          ______________________________________                                         Experimental reproduction of MSD.                                                         No. of piglets                                                      length     at birth     No. of  LA.sup.1 in piglets                            of         alive   dead     deaths                                                                               born  died in                                sow   gestation                                                                               (number Ab pos).sup.2                                                                       week 1                                                                               dead  week 1                                 ______________________________________                                          52   113      12(5)   3(2)   6     2     4                                    965   116       3(0)   9(3)   2     4                                          997   114       9(0)   1(0)   0                                                1305  116       7(0)   2(0)   1                                                134   109       4(4)   7(4)   4     3                                          941   117      7       10                                                      1056  113       7(1)   3(0)   4                                                1065  115      9        2                                                      ______________________________________                                          .sup.1 LA was isolated from lung, liver, spleen, kidney, or ascitic            fluids.                                                                        .sup.2 Antibodies directed against LA were detected in serum samples take      before the piglets had sucked, or were detected in ascitic fluids of           piglets born dead.                                                       

                  TABLE 7                                                          ______________________________________                                         Reactivity in IPMA of a collection of field sera from Europe                   and North-America tested with LA isolates from the Netherlands                 (NL1 and NL2), Germany (GE1 and GE2), and the United States                    (US1, US2 and US3).                                                            Isolates:   NL1    NL2    GE1  GE2  US1  US2  US3                              ______________________________________                                         Sera from:                                                                     The Netherlands                                                                TH-187      3.5.sub.t                                                                             3.5    2.5  3.5  -    -    -                                TO-36       3.5    3.0    2.5  3.0  -    1.0  -                                Germany                                                                        BE-352      4.0    3.5    2.5  3.0  -    1.5  -                                BE-392      3.5    3.5    2.5  2.5  1.5  1.5  0.5                              NI-f2       2.5    1.5    2.0  2.5  -    -    -                                United Kingdom                                                                 PA-141615   4.0    3.0    3.0  3.5  -    -    -                                PA-141617   4.0    3.5    3.0  3.5  -    2.5  2.0                              PA-142440   3.5    3.0    2.5  3.5  -    2.0  2.5                              Belgium                                                                        PE-1960     4.5    4.5    3.0  4.0  1.5  -    -                                France                                                                         EA-2975     4.0    3.5    3.0  3.0  2.0  -    -                                EA-2985     3.5    3.0    3.0  2.5  -    -    -                                United States                                                                  SL-441      3.5    1.5    2.5  2.5  3.5  3.5  3.0                              SL-451      3.0    2.0    2.5  2.5  3.5  4.5  4.0                              AL-RP9577   1.5    -      -    1.0  3.0  4.0  2.5                              AL-P10814/33                                                                               0.5    2.5    -    -    2.5  3.5  3.0                              AL-4094A    -      -      -    -    1.0  2.0  0.5                              AL-7525     -      -      -    -    -    1.0  -                                JC-MN41     -      -      -    -    1.0  3.5  1.0                              JC-MN44     -      -      -    -    2.0  3.5  2.0                              JC-MN45     -      -      -    -    2.0  3.5  2.5                              Canada                                                                         RB-16       2.5    -      3.0  2.0  3.0  3.5  -                                RB-19       1.0    -      1.0  -    2.5  1.5  -                                RB-22       1.5    -      2.0  2.5  2.5  3.5  -                                RB-23       -      -      -    -    -    3.0  -                                ______________________________________                                          .sub.t = titre expressed as negative log; - = negative                   

                  TABLE 8                                                          ______________________________________                                         Reactivity in IPMA of a collection of experimental sera raised                 against LA and SIRSV tested with LA isolates from the                          Netherlands (NL1 and NL2), Germany (GE1 and GE2), and the                      United States (US1, US2 and US3).                                              Isolates: NL1    NL2    GE1  GE2  US1  US2   US3                               ______________________________________                                              Sera:                                                                          anti-LA:                                                                  21   14 dpi   2.5.sup.t                                                                             2.0  2.5  3.0  1.5  2.0   1.5                                  28 dpi   4.0    3.5  3.5  4.0  -    2.5   1.5                                  42 dpi   4.0    3.5  3.0  3.5  1.5  2.5   2.0                             23   14 dpi   3.0    2.0  2.5  3.0  1.0  2.0   1.0                                  28 dpi   3.5    3.5  3.5  4.0  1.5  2.0   2.0                                  42 dpi   4.0    4.0  3.0  4.0  -    2.5   2.5                             25   14 dpi   2.5    2.0  2.5  3.0  1.5  2.0   1.0                                  28 dpi   4.0    3.5  4.0  3.5  -    1.5   2.0                                  42 dpi   3.5    4.0  3.5  3.5  1.5  2.0   2.0                             29   14 dpi   3.5    3.5  3.0  3.5  -    2.0   1.5                                  28 dpi   3.5    3.5  3.0  3.5  -    2.5   2.0                                  42 dpi   4.0    3.5  3.5  4.0  1.5  2.5   2.5                                  anti-                                                                          SISRV:                                                                    2B   20 dpi   -      -    -    -    2.0  2.0   -                                    36 dpi   -      -    -    -    1.5  2.0   -                                    63 dpi   -      -    -    -    1.0  1.0   -                               9G   30 dpi   -      -    -    -    2.5  3.0   -                                    44 dpi   -      -    -    -    2.5  3.5   -                                    68 dpi   -      -    -    -    2.0  3.5   1.5                             16W  25 dpi   -      -    -    -    2.0  3.0   -                                    40 dpi   -      -    -    -    2.0  3.0   -                                    64 dpi   -      -    -    -    2.5  2.5   1.5                             16Y  36 dpi   -      -    -    -    1.0  3.0   1.0                                  64 dpi   -      -    -    -    2.5  3.0   -                               ______________________________________                                          .sup.t = titer expressed as negative log; - = negative                   

                                      TABLE 9                                      __________________________________________________________________________     Characteristics of the ORFs of Lelystad Virus.                                                      Calculated                                                                     size of the                                                                            number of                                              Nucleotides                                                                            No. of amino                                                                           unmodified                                                                             glycosylation                                     ORF  (first-last)                                                                           acids   peptide (kDa)                                                                          sites                                             __________________________________________________________________________     ORF1A                                                                                212-7399                                                                              2396    260.0   3 (SEQ ID NO: 2)                                  ORF1B                                                                                7384-11772                                                                            1463    161.8   3 (SEQ ID NO: 3)                                  ORF2 11786-12532                                                                            249     28.4    2 (SEQ ID NO: 4)                                  ORF3 12394-13188                                                                            265     30.6    7 (SEQ ID NO: 5)                                       12556-13188                                                                            211     24.5    4 (SEQ ID NO: 6)                                  ORF4 12936-13484                                                                            183     20.0    4                                                      12981-13484                                                                            168     18.4    4                                                      13068-13484                                                                            139     15.4    3                                                 ORF5 13484-14086                                                                            201     22.4    2 (SEQ ID NO: 7)                                  ORF6 14077-14595                                                                            173     18.9    2 (SEQ ID NO: 8)                                  ORF7 14588-14971                                                                            128     13.8    1 (SEQ ID NO: 9)                                  __________________________________________________________________________

References

Boer, G. F. de, Back, W., and Osterhaus, A. D. M. E., (1990) An ELISA for detection of antibodies against influenza A nucleoprotein in human and various animal species, Arch. Virol. 115, 47-61.

Boursnell, M. E. G., Brown, T. D. K., and Binns, M. M., (1984) Sequence of the membrane protein gene from avian coronavirus IBV, Virus Res. 1, 303-314.

Boursnell, M. E. G., Brown, T. D. K., Foulds, I. J., Green, P. F., Tomley F. M., and Binns, M. M., (1987) Completion of the sequence of the genome of the coronavirus avian infectious bronchitis virus, J. Gen. Virol. 68, 57-77.

Brakke, M. K., (1967) In: Methods in Virology, Volume II, pp. 93-117 (Edited by K. Maramorosch and H. Koprowski) New York, Academic Press.

Bredenbeek, P. J., Pachuk, C. J., Noten, J. F. H., Charit e, J., Luytjes, W., Weiss, S. R., and Spaan, W. J. M., (1990) The primary structure and expression of the second open reading frame of the polymerase gene of coronavirus MHV-A59. Nucleic Acids Res. 18, 1825-1832.

Brenner, S., and Horne, R. W., (1959) A negative staining method for high resolution electron microscopy of viruses, Biochimica et Biophysica Acta 34, 103-110.

Brinton-Darnell, M., and Plagemann, P. G., (1975) Structure and chemical-physical characteristics of lactate dehydrogenase-elevating virus and its RNA, J. Virol. 16, 420-433.

Favaloro, J., Treisman, R. & Kamen, R., (1980) In: Methods in Enzymology, vol. 65, 718-749 (eds. Grossman, L. & Moldave, K.) Academic Press, New York.

Godeny, E. K., Speicher, D. W., and Brinton, M. A., (1990) Map location of lactate dehydrogenase-elevating virus (LDV) capsid protein (Vp1) gene, Virology, 177, 768-771.

Grist, N. R., Ross, C. A., and Bell, E. J., (1974) In: Diagnostic Methods in Clinical Virology, p. 120, Oxford, Blackwell Scientific Publications.

G ubler, U., and Hoffman, B. J., (1983) A simple and very efficient method for generating cDNA libraries, Gene 25, 263-269.

Hanahan, D., (1985) In: DNA Cloning I; A Practical Approach, Chapter 6, 109-135.

Hill, H., (1990) Overview and History of Mystery Swine Disease (Swine Infertility Respiratory Syndrome), In: Proceedings of the Mystery Swine Disease Committee Meeting, Oct. 6, 1990, Denver, Colo., Livestock Conservation Institute, Madison Wis., USA.

Hirsch, J. G. & Fedorko, M. E., (1968) Ultrastructure of human leucocytes after simultaneous fixation with glutaraldehyde and osmiumtetroxide and postfixation in uranylacetate, Journal of Cellular Biology 38, 615.

Horzinek, M. C., Maess, J., and Laufs, R., (1971) Studies on the substructure of togaviruses II. Analysis of equine arteritis, rubella, bovine viral diarrhea and hog cholera viruses, Arch. Gesamte Virusforsch. 33, 306-318.

Hyllseth, B., (1973) Structural proteins of equine arteritis virus, Arch. Gesamte Virusforsch. 40, 177-188.

Kasza, L., Shadduck, J. A., and Christoffinis, G. J., (1972) Establishment, viral susceptibility and biological characteristics of a swine kidney cell line SK-6, Res. Vet. Sci. 13, 46-51.

Loula, T., (1990) Clinical Presentation of Mystery Pig Disease in the breeding herd and suckling piglets, In: Proceedings of the Mystery Swine Disease Committee Meeting, Oct. 6, 1990, Denver, Colo., Livestock Conservation Institute, Madison, Wis., USA.

Masurel, N., (1976) Swine influenza virus and the recycling of influenza A viruses in man, Lancet ii, 244-247.

Mazancourt, A. de, Waxham, M. N., Nicholas, J. C., & Wolinsky, J. S., (1986) Antibody response to the rubella virus structural proteins in infants with the congenital rubella syndrome. J. Med. Virol. 19, 111-122.

Mengeling, W. L., and Lager, K. M., (1990) Mystery Pig Disease: Evidence and considerations for its etiology, In: Proceedings of the Mystery Swine Disease Committee Meeting, Oct. 6, 1990, Denver, Colo., Livestock Conservation Institute, Madison, Wis., USA.

Moormann, R. J. M., and Hulst, M. M., (1988) Hog cholera virus: identification and characterization of the viral RNA and virus-specific RNA synthesized in infected swine kidney cells, Virus Res. 11, 281-291.

Moormann, R. J. M., Warmerdam, P. A. M., van der Meer, B., Schaaper, W. M. M., Wensvoort, G., and Hulst, M. M., (1990) Molecular cloning and nucleotide sequence of hog cholera virus strain Brescia and mapping of the genomic region encoding envelope protein E1, Virology, 177, 184-198.

Oirschot, J. T. van, Houwers, D. J., Rziha, H. J., and Moonen, P. J. L. M., (1988) Development of an ELISA for detection of antibodies to glycoprotein I of Aujeszky's disease virus: a method for the serological differentiation between infected and vaccinated pigs, J. Virol. Meth. 22, 191-206.

Pearson, W. R., and Lipman, D. J., (1988) Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA 85, 2444-2448.

Reed, L. J., and Muench, H., (1938) A simple method of estimating fifty percent endpoints, Am. J. Hyg. 27, 493-497.

Rottier, P. J. M., Welling, G. W., Welling-Wester, S., Niesters, H. G. M., Lenstra, J. M., and van der Zeijst, B. A. M., (1986) Predicted membrane topology of the coronavirus protein E1. Biochemistry 25, 1335-1339.

Sambrook, J., Fritsch, E. F., and Maniatis, T., (1989) Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Lab., Cold Spring Harbor, N.Y.

Sethna, P. B., Hung, S.-L., and Brian, D. A., (1989) Coronavirus subgenomic minus-strand RNAs and the potential for mRNA replicons, Proc. Natl. Acad. Sci. USA, 86, 5626-5630.

Setzer, D. R., McGrogan, M., Nunberg, J. H. & Schimke, R. T., (1980) Size heterogeneity in the 3'-end of the dehydrofolate reductase messenger RNA's in mouse cells, Cell 22, 361-370.

Snijder, E. J., den Boon, J. A., Bredenbeek, P. J., Horzinek, M. C., Rijnbrand, R., and Spaan, W. J. M., (1990a) The carboxyl-terminal part of the putative Berne virus polymerase is expressed by ribosomal frameshifting and contains sequence motifs which indicate that toro- and coronaviruses are evolutionary related, Nucleic Acids Res. 18, 4535-4542.

Snijder, E. J., Horzinek, M. C., and Spaan, W. J. M., (1990b) A 3'-coterminal nested set of independently transcribed messenger RNAs is generated during Berne virus replication. J. Virol. 64, 355-363.

Spaan, W. J. M., Cavanagh, D., and Horzinek, M. C., (1988) Coronaviruses: structure and genome expression. J. Gen. Virol. 69, 2939-2952.

Strauss, W. M., (1987) Preparation of genomic DNA from mammalian tissue, In: Current protocols in molecular biology (eds. Ausubel F. M. et al.) 2.2.1 John Wiley & Sons, New York.

Terpstra, C., (1978) Detection of Border disease antigen in tissues of affected sheep and in cell cultures by immunofluorescence, Res. Vet. Sci. 25, 350-355.

Venable, J. H. & Coggeshall, R., (1965) A simplified lead citrate stain for use in electronmicroscopy, Journal of Cellular Biology 25, 407.

Vries, A. A. F. de, Chirnside, E. D., Bredenbeek, P. J., Gravestein, L. A., Horzinek, M. C., and Spaan, W. J. M., (1990) All subgenomic mRNAs of equine arteritis virus contain a common leader sequence, Nucleic Acids Res. 18, 3241-3247.

Wensvoort, G., and Terpstra, C., (1988) Bovine viral diarrhoea infections in piglets from sows vaccinated against swine fever with contaminated vaccine, Res. Vet. Sci. 45, 143-148.

Wensvoort, G., Terpstra, C., and Bloemraad, M., (1988) An enzyme immunoassay, employing monoclonal antibodies and detecting specifically antibodies against classical swine fever virus, Vet. Microbiol. 17, 129-140.

Wensvoort, G., Terpstra, C., Boonsta, J., Bloemraad, M., and Zaane, D. van, (1986) Production of monoclonal antibodies against swine fever virus and their use in laboratory diagnosis, Vet. Microbiol. 12, 101-108.

Wensvoort, G., Terpstra, C., and Kluyver, E. P. de, (1988) Characterization of porcine and some ruminant pestiviruses by cross-neutralization, Vet. Microbiol. 20, 291-306.

Westenbrink, F., Middel, W. G. J., Straver, P., and Leeuw, P. W. de, (1986) A blocking enzyme-linked immunosorbent assay (ELISA) for bovine virus diarrhoea virus serology, J. Vet. Med. B33, 354-361.

Westenbrink, F., Veldhuis, M. A., and Brinkhof, J. M. A., (1989) An enzyme-linked immunosorbent assay for detection of antibodies to porcine parvo virus, J. Virol. Meth. 23, 169-178.

Zeijst, B. A. M. van der, Horzinek, M. C., and Moenning, V., (1975) The genome of equine arteritis virus, Virology, 68, 418-425.

    __________________________________________________________________________     SEQUENCE LISTING                                                               (1) GENERAL INFORMATION:                                                       (iii) NUMBER OF SEQUENCES: 9                                                   (2) INFORMATION FOR SEQ ID NO:1:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 15108 base pairs                                                   (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: DNA (genomic)                                              (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 212..7399                                                        (D) OTHER INFORMATION:                                                         (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 7384..11772                                                      (D) OTHER INFORMATION:                                                         (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 11786..12532                                                     (D) OTHER INFORMATION:                                                         (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 12394..13188                                                     (D) OTHER INFORMATION:                                                         (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 12936..13484                                                     (D) OTHER INFORMATION:                                                         (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 13484..14086                                                     (D) OTHER INFORMATION:                                                         (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 14077..14595                                                     (D) OTHER INFORMATION:                                                         (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 14588..14971                                                     (D) OTHER INFORMATION:                                                         (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                        GGGTATTCCCCCTACATACACGACACTTCTAGTGTTTGTGTACCTTGGAGGCGTGGGTAC60                 AGCCCCGCCCCACCCCTTGGCCCCTGTTCTAGCCCAACAGGTATCCTTCTCTCTCGGGGC120                GAGTGCGCCGCCTGCTGCTCCCTTGCAGCGGGAAGGACCTCCCGAGTATTTCCGGAGAGC180                ACCTGCTTTACGGGATCTCCACCCTTTAACCATGTCTGGGACGTTCTCCCG231                         GTGCATGTGCACCCCGGCTGCCCGGGTATTTTGGAACGCCGGCCAAGTCTTTTGCACACG291                GTGTCTCAGTGCGCGGTCTCTTCTCTCTCCAGAGCTTCAGGACACTGACCTCGGTGCAGT351                TGGCTTGTTTTACAAGCCTAGGGACAAGCTTCACTGGAAAGTCCCTATCGGCATCCCTCA411                GGTGGAATGTACTCCATCCGGGTGCTGTTGGCTCTCAGCTGTTTTCCCTTTGGCGCGTAT471                GACCTCCGGCAATCACAACTTCCTCCAACGACTTGTGAAGGTTGCTGATGTTTTGTACCG531                TGACGGTTGCTTGGCACCTCGACACCTTCGTGAACTCCAAGTTTACGAGCGCGGCTGCAA591                CTGGTACCCGATCACGGGGCCCGTGCCCGGGATGGGTTTGTTTGCGAACTCCATGCACGT651                ATCCGACCAGCCGTTCCCTGGTGCCACCCATGTGTTGACTAACTCGCCTTTGCCTCAACA711                GGCTTGTCGGCAGCCGTTCTGTCCATTTGAGGAGGCTCATTCTAGCGTGTACAGGTGGAA771                GAAATTTGTGGTTTTCACGGACTCCTCCCTCAACGGTCGATCTCGCATGATGTGGACGCC831                GGAATCCGATGATTCAGCCGCCCTGGAGGTACTACCGCCTGAGTTAGAACGTCAGGTCGA891                AATCCTCATTCGGAGTTTTCCTGCTCATCACCCTGTCGACCTGGCCGACTGGGAGCTCAC951                TGAGTCCCCTGAGAACGGTTTTTCCTTCAACACGTCTCATTCTTGCGGTCACCTTGTCCA1011               GAACCCCGACGTGTTTGATGGCAAGTGCTGGCTCTCCTGCTTTTTGGGCCAGTCGGTCGA1071               AGTGCGCTGCCATGAGGAACATCTAGCTGACGCCTTCGGTTACCAAACCAAGTGGGGCGT1131               GCATGGTAAGTACCTCCAGCGCAGGCTTCAAGTTCGCGGCATTCGTGCTGTAGTCGATCC1191               TGATGGTCCCATTCACGTTGAAGCGCTGTCTTGCCCCCAGTCTTGGATCAGGCACCTGAC1251               TCTGGATGATGATGTCACCCCAGGATTCGTTCGCCTGACATCCCTTCGCATTGTGCCGAA1311               CACAGAGCCTACCACTTCCCGGATCTTTCGGTTTGGAGCGCATAAGTGGTATGGCGCTGC1371               CGGCAAACGGGCTCGTGCTAAGCGTGCCGCTAAAAGTGAGAAGGATTCGGCTCCCACCCC1431               CAAGGTTGCCCTGCCGGTCCCCACCTGTGGAATTACCACCTACTCTCCACCGACAGACGG1491               GTCTTGTGGTTGGCATGTCCTTGCCGCCATAATGAACCGGATGATAAATGGTGACTTCAC1551               GTCCCCTCTGACTCAGTACAACAGACCAGAGGATGATTGGGCTTCTGATTATGATCTTGT1611               TCAGGCGATTCAATGTCTACGACTGCCTGCTACCGTGGTTCGGAATCGCGCCTGTCCTAA1671               CGCCAAGTACCTTATAAAACTTAACGGAGTTCACTGGGAGGTAGAGGTGAGGTCTGGAAT1731               GGCTCCTCGCTCCCTTTCTCGTGAATGTGTGGTTGGCGTTTGCTCTGAAGGCTGTGTCGC1791               ACCGCCTTATCCAGCAGACGGGCTACCTAAACGTGCACTCGAGGCCTTGGCGTCTGCTTA1851               CAGACTACCCTCCGATTGTGTTAGCTCTGGTATTGCTGACTTTCTTGCTAATCCACCTCC1911               TCAGGAATTCTGGACCCTCGACAAAATGTTGACCTCCCCGTCACCAGAGCGGTCCGGCTT1971               CTCTAGTTTGTATAAATTACTATTAGAGGTTGTTCCGCAAAAATGCGGTGCCACGGAAGG2031               GGCTTTCATCTATGCTGTTGAGAGGATGTTGAAGGATTGTCCGAGCTCCAAACAGGCCAT2091               GGCCCTTCTGGCAAAAATTAAAGTTCCATCCTCAAAGGCCCCGTCTGTGTCCCTGGACGA2151               GTGTTTCCCTACGGATGTTTTAGCCGACTTCGAGCCAGCATCTCAGGAAAGGCCCCAAAG2211               TTCCGGCGCTGCTGTTGTCCTGTGTTCACCGGATGCAAAAGAGTTCGAGGAAGCAGCCCC2271               RGAAGAAGTTCAAGAGAGTGGCCACAAGGCCGTCCACTCTGCACTCCTTGCCGAGGGTCC2331               TAACAATGAGCAGGTACAGGTGGTTGCCGGTGAGCAACTGAAGCTCGGCGGTTGTGGTTT2391               GGCAGTCGGGAATGCTCATGAAGGTGCTCTGGTCTCAGCTGGTCTAATTAACCTGGTAGG2451               CGGGAATTTGTCCCCCTCAGACCCCATGAAAGAAAACATGCTCAATAGCCGGGAAGACGA2511               ACCACTGGATTTGTCCCAACCAGCACCAGCTTCCACAACGACCCTTGTGAGAGAGCAAAC2571               ACCCGACAACCCAGGTTCTGATGCCGGTGCCCTCCCCGTCACCGTTCGAGAATTTGTCCC2631               GACGGGGCCTATACTCTGTCATGTTGAGCACTGCGGCACGGAGTCGGGCGACAGCAGTTC2691               GCCTTTGGATCTATCTGATGCGCAAACCCTGGACCAGCCTTTAAATCTATCCCTGGCCGC2751               TTGGCCAGTGAGGGCCACCGCGTCTGACCCTGGCTGGGTCCACGGTAGGCGCGAGCCTGT2811               CTTTGTAAAGCCTCGAAATGCTTTCTCTGATGGCGATTCAGCCCTTCAGTTCGGGGAGCT2871               TTCTGAATCCAGCTCTGTCATCGAGTTTGACCGGACAAAAGATGCTCCGGTGGTTGACGC2931               CCCTGTCGACTTGACGACTTCGAACGAGGCCCTCTCTGTAGTCGATCCTTTCGAATTTGC2991               CGAACTCAAGCGCCCGCGTTTCTCCGCACAAGCCTTAATTGACCGAGGCGGTCCACTTGC3051               CGATGTCCATGCAAAAATAAAGAACCGGGTATATGAACAGTGCCTCCAAGCTTGTGAGCC3111               CGGTAGTCGTGCAACCCCAGCCACCAGGGAGTGGCTCGACAAAATGTGGGATAGGGTGGA3171               CATGAAAACTTGGCGCTGCACCTCGCAGTTCCAAGCTGGTCGCATTCTTGCGTCCCTCAA3231               ATTCCTCCCTGACATGATTCAAGACACACCGCCTCCTGTTCCCAGGAAGAACCGAGCTAG3291               TGACAATGCCGGCCTGAAGCAACTGGTGGCACAGTGGGATAGGAAATTGAGTGTGACCCC3351               CCCCCCAAAACCGGTTGGGCCAGTGCTTGACCAGATCGTCCCTCCGCCTACGGATATCCA3411               GCAAGAAGATGTCACCCCCTCCGATGGGCCACCCCATGCGCCGGATTTTCCTAGTCGAGT3471               GAGCACGGGCGGGAGTTGGAAAGGCCTTATGCTTTCCGGCACCCGTCTCGCGGGGTCTAT3531               CAGCCAGCGCCTTATGACATGGGTTTTTGAAGTTTTCTCCCACCTCCCAGCTTTTATGCT3591               CACACTTTTCTCGCCGCGGGGCTCTATGGCTCCAGGTGATTGGTTGTTTGCAGGTGTCGT3651               TTTACTTGCTCTCTTGCTCTGTCGTTCTTACCCGATACTCGGATGCCTTCCCTTATTGGG3711               TGTCTTTTCTGGTTCTTTGCGGCGTGTTCGTCTGGGTGTTTTTGGTTCTTGGATGGCTTT3771               TGCTGTATTTTTATTCTCGACTCCATCCAACCCAGTCGGTTCTTCTTGTGACCACGATTC3831               GCCGGAGTGTCATGCTGAGCTTTTGGCTCTTGAGCAGCGCCAACTTTGGGAACCTGTGCG3891               CGGCCTTGTGGTCGGCCCCTCAGGCCTCTTATGTGTCATTCTTGGCAAGTTACTCGGTGG3951               GTCACGTTATCTCTGGCATGTTCTCCTACGTTTATGCATGCTTGCAGATTTGGCCCTTTC4011               TCTTGTTTATGTGGTGTCCCAGGGGCGTTGTCACAAGTGTTGGGGAAAGTGTATAAGGAC4071               AGCTCCTGCGGAGGTGGCTCTTAATGTATTTCCTTTCTCGCGCGCCACCCGTGTCTCTCT4131               TGTATCCTTGTGTGATCGATTCCAAACGCCAAAAGGGGTTGATCCTGTGCACTTGGCAAC4191               GGGTTGGCGCGGGTGCTGGCGTGGTGAGAGCCCCATCCATCAACCACACCAAAAGCCCAT4251               AGCTTATGCCAATTTGGATGAAAAGAAAATGTCTGCCCAAACGGTGGTTGCTGTCCCATA4311               CGATCCCAGTCAGGCTATCAAATGCCTGAAAGTTCTGCAGGCGGGAGGGGCCATCGTGGA4371               CCAGCCTACACCTGAGGTCGTTCGTGTGTCCGAGATCCCCTTCTCAGCCCCATTTTTCCC4431               AAAAGTTCCAGTCAACCCAGATTGCAGGGTTGTGGTAGATTCGGACACTTTTGTGGCTGC4491               GGTTCGCTGCGGTTACTCGACAGCACAACTGGTYCTGGGCCGGGGCAACTTTGCCAAGTT4551               AAATCAGACCCCCCCCAGGAACTCTATCTCCACCAAAACGACTGGTGGGGCCTCTTACAC4611               CCTTGCTGTGGCTCAAGTGTCTGCGTGGACTCTTGTTCATTTCATCCTCGGTCTTTGGTT4671               CACATCACCTCAAGTGTGTGGCCGAGGAACCGCTGACCCATGGTGTTCAAATCCTTTTTC4731               ATATCCTACCTATGGCCCCGGAGTTGTGTGCTCCTCTCGACTTTGTGTGTCTGCCGACGG4791               GGTCACCCTGCCATTGTTCTCAGCCGTGGCACAACTCTCCGGTAGAGAGGTGGGGATTTT4851               TATTTTGGTGCTCGTCTCCTTGACTGCTTTGGCCCACCGCATGGCTCTTAAGGCAGACAT4911               GTTAGTGGTCTTTTCGGCTTTTTGTGCTTACGCCTGGCCCATGAGCTCCTGGTTAATCTG4971               CTTCTTTCCTATACTCTTGAAGTGGGTTACCCTTCACCCTCTTACTATGCTTTGGGTGCA5031               CTCATTCTTGGTGTTTTGTCTGCCAGCAGCCGGCATCCTCTCACTAGGGATAACTGGCCT5091               TCTTTGGGCAATTGGCCGCTTTACCCAGGTTGCCGGAATTATTACACCTTATGACATCCA5151               CCAGTACACCTCTGGGCCACGTGGTGCAGCTGCTGTGGCCACAGCCCCAGAAGGCACTTA5211               TATGGCCGCCGTCCGGAGAGCTGCTTTAACTGGGCGAACTTTAATCTTCACCCCGTCTGC5271               AGTTGGATCCCTTCTCGAAGGTGCTTTCAGGACTCATAAACCCTGCCTTAACACCGTGAA5331               TGTTGTAGGCTCTTCCCTTGGTTCCGGAGGGGTTTTCACCATTGATGGCAGAAGAACTGT5391               CGTCACTGCTGCCCATGTGTTGAACGGCGACACAGCTAGAGTCACCGGCGACTCCTACAA5451               CCGCATGCACACTTTCAAGACCAATGGTGATTATGCCTGGTCCCATGCTGATGACTGGCA5511               GGGCGTTGCCCCTGTGGTCAAGGTTGCGAAGGGGTACCGCGGTCGTGCCTACTGGCAAAC5571               ATCAACTGGTGTCGAACCCGGTATCATTGGGGAAGGGTTCGCCTTCTGTTTTACTAACTG5631               CGGCGATTCGGGGTCACCCGTCATCTCAGAATCTGGTGATCTTATTGGAATCCACACCGG5691               TTCAAACAAACTTGGTTCTGGTCTTGTGACAACCCCTGAAGGGGAGACCTGCACCATCAA5751               AGAAACCAAGCTCTCTGACCTTTCCAGACATTTTGCAGGCCCAAGCGTTCCTCTTGGGGA5811               CATTAAATTGAGTCCGGCCATCATCCCTGATGTAACATCCATTCCGAGTGACTTGGCATC5871               GCTCCTAGCCTCCGTCCCTGTAGTGGAAGGCGGCCTCTCGACCGTTCAACTTTTGTGTGT5931               CTTTTTCCTTCTCTGGCGCATGATGGGCCATGCCTGGACACCCATTGTTGCCGTGGGCTT5991               CTTTTTGCTGAATGAAATTCTTCCAGCAGTTTTGGTCCGAGCCGTGTTTTCTTTTGCACT6051               CTTTGTGCTTGCATGGGCCACCCCCTGGTCTGCACAGGTGTTGATGATTAGACTCCTCAC6111               GGCATCTCTCAACCGCAACAAGCTTTCTCTGGCGTTCTACGCACTCGGGGGTGTCGTCGG6171               TTTGGCAGCTGAAATCGGGACTTTTGCTGGCAGATTGTCTGAATTGTCTCAAGCTCTTTC6231               GACATACTGCTTCTTACCTAGGGTCCTTGCTATGACCAGTTGTGTTCCCACCATCATCAT6291               TGGTGGACTCCATACCCTCGGTGTGATTCTGTGGTTRTTCAAATACCGGTGCCTCCACAA6351               CATGCTGGTTGGTGATGGGAGTTTTTCAAGCGCCTTCTTCCTACGGTATTTTGCAGAGGG6411               TAATCTCAGAAAAGGTGTTTCACAGTCCTGTGGCATGAATAACGAGTCCCTAACGGCTGC6471               TTTAGCTTGCAAGTTGTCACAGGCTGACCTTGATTTTTTGTCCAGCTTAACGAACTTCAA6531               GTGCTTTGTATCTGCTTCAAACATGAAAAATGCTGCCGGCCAGTACATTGAAGCAGCGTA6591               TGCCAAGGCCCTGCGCCAAGAGTTGGCCTCTCTAGTTCAGATTGACAAAATGAAAGGAGT6651               TTTGTCCAAGCTCGAGGCCTTTGCTGAAACAGCCACCCCGTCCCTTGACATAGGTGACGT6711               GATTGTTCTGCTTGGGCAACATCCTCACGGATCCATCCTCGATATTAATGTGGGGACTGA6771               AAGGAAAACTGTGTCCGTGCAAGAGACCCGGAGCCTAGGCGGCTCCAAATTCAGTGTTTG6831               TACTGTCGTGTCCAACACACCCGTGGACGCCTTRACCGGCATCCCACTCCAGACACCAAC6891               CCCTCTTTTTGAGAATGGTCCGCGTCATCGCAGCGAGGAAGACGATCTTAAAGTCGAGAG6951               GATGAAGAAACACTGTGTATCCCTCGGCTTCCACAACATCAATGGCAAAGTTTACTGCAA7011               AATTTGGGACAAGTCTACCGGTGACACCTTTTACACGGATGATTCCCGGTACACCCAAGA7071               CCATGCTTTTCAGGACAGGTCAGCCGACTACAGAGACAGGGACTATGAGGGTGTGCAAAC7131               CACCCCCCAACAGGGATTTGATCCAAAGTCTGAAACCCCTGTTGGCACTGTTGTGATCGG7191               CGGTATTACGTATAACAGGTATCTGATCAAAGGTAAGGAGGTTCTGGTCCCCAAGCCTGA7251               CAACTGCCTTGAAGCTGCCAAGCTGTCCCTTGAGCAAGCTCTCGCTGGGATGGGCCAAAC7311               TTGCGACCTTACAGCTGCCGAGGTGGAAAAGCTAAAGCGCATCATTAGTCAACTCCAAGG7371               TTTGACCACTGAACAGGCTTTAAACTGTTAGCCGCCAGCGGCTTGACCCGCTGTGGCC7429                 GCGGCGGCCTAGTTGTGACTGAAACGGCGGTAAAAATTATAAAATACCACAGCAGAACTT7489               TCACCTTAGGCCCTTTAGACCTAAAAGTCACTTCCGAGGTGGAGGTAAAGAAATCAACTG7549               AGCAGGGCCACGCTGTTGTGGCAAACTTATGTTCCGGTGTCATCTTGATGAGACCTCACC7609               CACCGTCCCTTGTCGACGTTCTTCTGAAACCCGGACTTGACACAATACCCGGCATTCAAC7669               CAGGGCATGGGGCCGGGAATATGGGCGTGGACGGTTCTATTTGGGATTTTGAAACCGCAC7729               CCACAAAGGCAGAACTCGAGTTATCCAAGCAAATAATCCAAGCATGTGAAGTTAGGCGCG7789               GGGACGCCCCGAACCTCCAACTCCCTTACAAGCTCTATCCTGTTAGGGGGGATCCTGAGC7849               GGCATAAAGGCCGCCTTATCAATACCAGGTTTGGAGATTTACCTTACAAAACTCCTCAAG7909               ACACCAAGTCCGCAATCCACGCGGCTTGTTGCCTGCACCCCAACGGGGCCCCCGTGTCTG7969               ATGGTAAATCCACACTAGGTACCACTCTTCAACATGGTTTCGAGCTTTATGTCCCTACTG8029               TGCCCTATAGTGTCATGGAGTACCTTGATTCACGCCCTGACACCCCTTTTATGTGTACTA8089               AACATGGCACTTCCAAGGCTGCTGCAGAGGACCTCCAAAAATACGACCTATCCACCCAAG8149               GATTTGTCCTGCCTGGGGTCCTACGCCTAGTACGCAGATTCATCTTTGGCCATATTGGTA8209               AGGCGCCGCCATTGTTCCTCCCATCAACCTATCCCGCCAAGAACTCTATGGCAGGGATCA8269               ATGGCCAGAGGTTCCCAACAAAGGACGTTCAGAGCATACCTGAAATTGATGAAATGTGTG8329               CCCGCGCTGTCAAGGAGAATTGGCAAACTGTGACACCTTGCACCCTCAAGAAACAGTACT8389               GTTCCAAGCCCAAAACCAGGACCATCCTGGGCACCAACAACTTTATTGCCTTGGCTCACA8449               GATCGGCGCTCAGTGGTGTCACCCAGGCATTCATGAAGAAGGCTTGGAAGTCCCCAATTG8509               CCTTGGGGAAAAACAAATTCAAGGAGCTGCATTGCACTGTCGCCGGCAGGTGTCTTGAGG8569               CCGACTTGGCCTCCTGTGACCGCAGCACCCCCGCCATTGTAAGATGGTTTGTTGCCAACC8629               TCCTGTATGAACTTGCAGGATGTGAAGAGTACTTGCCTAGCTATGTGCTTAATTGCTGCC8689               ATGACCTCGTGGCAACACAGGATGGTGCCTTCACAAAACGCGGTGGCCTGTCGTCCGGGG8749               ACCCCGTCACCAGTGTGTCCAACACCGTATATTCACTGGTAATTTATGCCCAGCACATGG8809               TATTGTCGGCCTTGAAAATGGGTCATGAAATTGGTCTTAAGTTCCTCGAGGAACAGCTCA8869               AGTTCGAGGACCTCCTTGAAATTCAGCCTATGTTGGTATACTCTGATGATCTTGTCTTGT8929               ACGCTGAAAGACCCACMTTTCCCAATTACCACTGGTGGGTCGAGCACCTTGACCTGATGC8989               TGGGTTTCAGAACGGACCCAAAGAAAACCGTCATAACTGATAAACCCAGCTTCCTCGGCT9049               GCAGAATTGAGGCAGGGCGACAGCTAGTCCCCAATCGCGACCGCATCCTGGCTGCTCTTG9109               CATATCACATGAAGGCGCAGAACGCCTCAGAGTATTATGCGTCTGCTGCCGCAATCCTGA9169               TGGATTCATGTGCTTGCATTGACCATGACCCTGAGTGGTATGAGGACCTCATCTGCGGTA9229               TTGCCCGGTGCGCCCGCCAGGATGGTTATAGCTTCCCAGGTCCGGCATTTTTCATGTCCA9289               TGTGGGAGAAGCTGAGAAGTCATAATGAAGGGAAGAAATTCCGCCACTGCGGCATCTGCG9349               ACGCCAAAGCCGACTATGCGTCCGCCTGTGGGCTTGATTTGTGTTTGTTCCATTCGCACT9409               TTCATCAACACTGCCCYGTCACTCTGAGCTGCGGTCACCATGCCGGTTCAAAGGAATGTT9469               CGCAGTGTCAGTCACCTGTTGGGGCTGGCAGATCCCCTCTTGATGCCGTGCTAAAACAAA9529               TTCCATACAAACCTCCTCGTACTGTCATCATGAAGGTGGGTAATAAAACAACGGCCCTCG9589               ATCCGGGGAGGTACCAGTCCCGTCGAGGTCTCGTTGCAGTCAAGAGGGGTATTGCAGGCA9649               ATGAAGTTGATCTTTCTGATGGRGACTACCAAGTGGTGCCTCTTTTGCCGACTTGCAAAG9709               ACATAAACATGGTGAAGGTGGCTTGCAATGTACTACTCAGCAAGTTCATAGTAGGGCCAC9769               CAGGTTCCGGAAAGACCACCTGGCTACTGAGTCAAGTCCAGGACGATGATGTCATTTACA9829               YACCCACCCATCAGACTATGTTTGATATAGTCAGTGCTCTCAAAGTTTGCAGGTATTCCA9889               TTCCAGGAGCCTCAGGACTCCCTTTCCCACCACCTGCCAGGTCCGGGCCGTGGGTTAGGC9949               TTATTGCCAGCGGGCACGTCCCTGGCCGAGTATCATACCTCGATGAGGCTGGATATTGTA10009              ATCATCTGGACATTCTTAGACTGCTTTCCAAAACACCCCTTGTGTGTTTGGGTGACCTTC10069              AGCAACTTCACCCTGTCGGCTTTGATTCCTACTGTTATGTGTTCGATCAGATGCCTCAGA10129              AGCAGCTGACCACTATTTACAGATTTGGCCCTAACATCTGCGCACGCATCCAGCCTTGTT10189              ACAGGGAGAAACTTGAATCTAAGGCTAGGAACACTAGGGTGGTTTTTACCACCCGGCCTG10249              TGGCCTTTGGTCAGGTGCTGACACCATACCATAAAGATCGCATCGGCTCTGCGATAACCA10309              TAGATTCATCCCAGGGGGCCACCTTTGATATTGTGACATTGCATCTACCATCGCCAAAGT10369              CCCTAAATAAATCCCGAGCACTTGTAGCCATCACTCGGGCAAGACACGGGTTGTTCATTT10429              ATGACCCTCATAACCAGCTCCAGGAGTTTTTCAACTTAACCCCTGAGCGCACTGATTGTA10489              ACCTTGTGTTCAGCCGTGGGGATGAGCTGGTAGTTCTGAATGCGGATAATGCAGTCACAA10549              CTGTAGCGAAGGCCCTTGAGACAGGTCCATCTCGATTTCGAGTATCAGACCCGAGGTGCA10609              AGTCTCTCTTAGCCGCTTGTTCGGCCAGTCTGGAAGGGAGCTGTATGCCACTACCGCAAG10669              TGGCACATAACCTGGGGTTTTACTTTTCCCCGGACAGTCCAACATTTGCACCTCTGCCAA10729              AAGAGTTGGCGCCACATTGGCCAGTGGTTACCCACCAGAATAATCGGGCGTGGCCTGATC10789              GACTTGTCGCTAGTATGCGCCCAATTGATGCCCGCTACAGCAAGCCAATGGTCGGTGCAG10849              GGTATGTGGTCGGGCCGTCCACCTTTCTTGGTACTCCTGGTGTGGTGTCATACTATCTCA10909              CACTATACATCAGGGGTGAGCCCCAGGCCTTGCCAGAAACACTCGTTTCAACAGGGCGTA10969              TAGCCACAGATTGTCGGGAGTATCTCGACGCGGCTGAGGAAGAGGCAGCAAAAGAACTCC11029              CCCACGCATTCATTGGCGATGTCAAAGGTACCACGGTTGGGGGGTGTCATCACATTACAT11089              CAAAATACCTACCTAGGTCCCTGCCTAAGGACTCTGTTGCCGTAGTTGGAGTAAGTTCGC11149              CCGGCAGGGCTGCTAAAGCCGTGTGCACTCTCACCGATGTGTACCTCCCCGAACTCCGGC11209              CATATCTGCAACCTGAGACGGCATCAAAATGCTGGAAACTCAAATTAGACTTCAGGGACG11269              TCCGACTAATGGTCTGGAAAGGAGCCACCGCCTATTTCCAGTTGGAAGGGCTTACATGGT11329              CGGCGCTGCCCGACTATGCCAGGTTYATTCAGCTGCCCAAGGATGCCGTTGTATACATTG11389              ATCCGTGTATAGGACCGGCAACAGCCAACCGTAAGGTCGTGCGAACCACAGACTGGCGGG11449              CCGACCTGGCAGTGACACCGTATGATTACGGTGCCCAGAACATTTTGACAACAGCCTGGT11509              TCGAGGACCTCGGGCCGCAGTGGAAGATTTTGGGGTTGCAGCCCTTTAGGCGAGCATTTG11569              GCTTTGAAAACACTGAGGATTGGGCAATCCTTGCACGCCGTATGAATGACGGCAAGGACT11629              ACACTGACTATAACTGGAACTGTGTTCGAGAACGCCCACACGCCATCTACGGGCGTGCTC11689              GTGACCATACGTATCATTTTGCCCCTGGCACAGAATTGCAGGTAGAGCTAGGTAAACCCC11749              GGCTGCCGCCTGGGCAAGTGCCGTGAATTCGGGGTGATGCAATGGGGTCACTG11802                     TGGAGTAAAATCAGCCAGCTGTTCGTGGACGCCTTCACTGAGTTCCTTGTTAGTGTGGTT11862              GATATTGYCATTTTCCTTGCCATACTGTTTGGGTTCACCGTCGCAGGATGGTTACTGGTC11922              TTTCTTCTCAGAGTGGTTTGCTCCGCGCTTCTCCGTTCGCGCTCTGCCATTCACTCTCCC11982              GAACTATCGAAGGTCCTATGAAGGCTTGTTGCCCAACTGCAGACCGGATGTCCCACAATT12042              TGCAGTCAAGCACCCATTGGGYATGTTTTGGCACATGCGAGTTTCCCACTTGATTGATGA12102              GRTGGTCTCTCGTCGCATTTACCAGACCATGGAACATTCAGGTCAAGCGGCCTGGAAGCA12162              GGTGGTTGGTGAGGCCACTCTCACGAAGCTGTCAGGGCTCGATATAGTTACTCATTTCCA12222              ACACCTGGCCGCAGTGGAGGCGGATTCTTGCCGCTTTCTCAGCTCACGACTCGTGATGCT12282              AAAAAATCTTGCCGTTGGCAATGTGAGCCTACAGTACAACACCACGTTGGACCGCGTTGA12342              GCTCATCTTCCCCACGCCAGGTACGAGGCCCAAGTTGACCGATTTCAGACAATGGCTCAT12402              CAGTGTGCACGCTTCCATTTTTTCCTCTGTGGCTTCATCTGTTACCTTGTTCATAGTGCT12462              TTGGCTTCGAATTCCAGCTCTACGCTATGTTTTTGGTTTCCATTGGCCCACGGCAACACA12522              TCATTCGAGCTGACCATCAACTACACCATATGCATGCCCTGTTCTACCAGTCAAGCGGCT12582              CGCCAAAGGCTCGAGCCCGGTCGTAACATGTGGTGCAAAATAGGGCATGACAGGTGTGAG12642              GAGCGTGACCATGATGAGTTGTTAATGTCCATCCCGTCCGGGTACGACAACCTCAAACTT12702              GAGGGTTATTATGCTTGGCTGGCTTTTTTGTCCTTTTCCTACGCGGCCCAATTCCATCCG12762              GAGTTGTTCGGGATAGGGAATGTGTCGCGCGTCTTCGTGGACAAGCGACACCAGTTCATT12822              TGTGCCGAGCATGATGGACACAATTCAACCGTATCTACCGGACACAACATCTCCGCATTA12882              TATGCGGCATATTACCACCACCAAATAGACGGGGGCAATTGGTTCCATTTGGAATGGCTG12942              CGGCCACTCTTTTCTTCCTGGCTGGTGCTCAACATATCATGGTTTCTGAGGCGTTCGCCT13002              GTAAGCCCTGTTTCTCGACGCATCTATCAGATATTGAGACCAACACGACCGCGGCTGCCG13062              GTTTCATGGTCCTTCAGGACATCAATTGTTTCCGACCTCACGGGGTCTCAGCAGCGCAAG13122              AGAAAATTTCCTTCGGAAAGTCGTCCCAATGTCGTGAAGCCGTCGGTACTCCCCAGTACA13182              TCACGATAACGGCTAACGTGACCGACGAATCATACTTGTACAACGCGGACCTGCTG13238                  ATGCTTTCTGCGTGCCTTTTCTACGCCTCAGAAATGAGCGAGAAAGGCTTCAAAGTCATC13298              TTTGGGAATGTCTCTGGCGTTGTTTCTGCTTGTGTCAATTTCACAGATTATGTGGCCCAT13358              GTGACCCAACATACCCAGCAGCATCATCTGGTAATTGATCACATTCGGTTGCTGCATTTC13418              CTGACACCATCTGCAATGAGGTGGGCTACAACCATTGCTTGTTTGTTCGCCATTCTCTTG13478              GCAATATGAGATGTTCTCACAAATTGGGGCGTTTCTTGACTCCGCACTCTTGCTTC13534                  TGGTGGCTTTTTTTGCTGTGTACCGGCTTGTCCTGGTCCTTTGCCGATGGCAACGGCGAC13594              AGCTCGACATACCAATACATATATAACTTGACGATATGCGAGCTGAATGGGACCGACTGG13654              TTGTCCAGCCATTTTGGTTGGGCAGTCGAGACCTTTGTGCTTTACCCGGTTGCCACTCAT13714              ATCCTCTCACTGGGTTTTCTCACAACAAGCCATTTTTTTGACGCGCTCGGTCTCGGCGCT13774              GTATCCACTGCAGGATTTGTTGGCGGGCGGTACGTACTCTGCAGCGTCTACGGCGCTTGT13834              GCTTTCGCAGCGTTCGTATGTTTTGTCATCCGTGCTGCTAAAAATTGCATGGCCTGCCGC13894              TATGCCCGTACCCGGTTTACCAACTTCATTGTGGACGACCGGGGGAGAGTTCATCGATGG13954              AAGTCTCCAATAGTGGTAGAAAAATTGGGCAAAGCCGAAGTCGATGGCAACCTCGTCACC14014              ATCAAACATGTCGTCCTCGAAGGGGTTAAAGCTCAACCCTTGACGAGGACTTCGGCTGAG14074              CAATGGGAGGCCTAGACGATTTTTGCAACGATCCTATCGCCGCACAAAAGCT14126                      CGTGCTAGCCTTTAGCATCACATACACACCTATAATGATATACGCCCTTAAGGTGTCACG14186              CGGCCGACTCCTGGGGCTGTTGCACATCCTAATATTTCTGAACTGTTCCTTTACATTCGG14246              ATACATGACATATGTGCATTTTCAATCCACCAACCGTGTCGCACTTACCCTGGGGGCTGT14306              TGTCGCCCTTCTGTGGGGTGTTTACAGCTTCACAGAGTCATGGAAGTTTATCACTTCCAG14366              ATGCAGATTGTGTTGCCTTGGCCGGCGATACATTCTGGCCCCTGCCCATCACGTAGAAAG14426              TGCTGCAGGTCTCCATTCAATCTCAGCGTCTGGTAACCGAGCATACGCTGTGAGAAAGCC14486              CGGACTAACATCAGTGAACGGCACTCTAGTACCAGGACTTCGGAGCCTCGTGCTGGGCGG14546              CAAACGAGCTGTTAAACGAGGAGTGGTTAACCTCGTCAAGTATGGCCGGTAAAAACCAG14605               AGCCAGAAGAAAAAGAAAAGTACAGCTCCGATGGGGAATGGCCAGCCAGTCAATCAACTG14665              TGCCAGTTGCTGGGTGCAATGATAAAGTCCCAGCGCCAGCAACCTAGGGGAGGACAGGCY14725              AAAAAGAAAAAGCCTGAGAAGCCACATTTTCCCCTGGCTGCTGAAGATGACATCCGGCAC14785              CACCTCACCCAGACTGAACGCTCCCTCTGCTTGCAATCGATCCAGACGGCTTTCAATCAA14845              GGCGCAGGAACTGCGTCRCTTTCATCCAGCGGGAAGGTCAGTTTTCAGGTTGAGTTTATG14905              CTGCCGGTTGCTCATACAGTGCGCCTGATTCGCGTGACTTCTACATCCGCCAGTCAGGGT14965              GCAAGTTAATTTGACAGTCAGGTGAATGGCCGCGATGGCGTGTGGCCTCTGAGTCA15021                  CCTATTCAATTAGGGCGATCACATGGGGGTCATACTTAATTCAGGCAGGAACCATGTGAC15081              CGAAATTAAAAAAAAAAAAAAAAAAAA15108                                               (2) INFORMATION FOR SEQ ID NO:2:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 2396 amino acids                                                   (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                        MetSerGlyThrPheSerArgCysMetCysThrProAlaAlaArgVal                               151015                                                                         PheTrpAsnAlaGlyGlnValPheCysThrArgCysLeuSerAlaArg                               202530                                                                         SerLeuLeuSerProGluLeuGlnAspThrAspLeuGlyAlaValGly                               354045                                                                         LeuPheTyrLysProArgAspLysLeuHisTrpLysValProIleGly                               505560                                                                         IleProGlnValGluCysThrProSerGlyCysCysTrpLeuSerAla                               65707580                                                                       ValPheProLeuAlaArgMetThrSerGlyAsnHisAsnPheLeuGln                               859095                                                                         ArgLeuValLysValAlaAspValLeuTyrArgAspGlyCysLeuAla                               100105110                                                                      ProArgHisLeuArgGluLeuGlnValTyrGluArgGlyCysAsnTrp                               115120125                                                                      TyrProIleThrGlyProValProGlyMetGlyLeuPheAlaAsnSer                               130135140                                                                      MetHisValSerAspGlnProPheProGlyAlaThrHisValLeuThr                               145150155160                                                                   AsnSerProLeuProGlnGlnAlaCysArgGlnProPheCysProPhe                               165170175                                                                      GluGluAlaHisSerSerValTyrArgTrpLysLysPheValValPhe                               180185190                                                                      ThrAspSerSerLeuAsnGlyArgSerArgMetMetTrpThrProGlu                               195200205                                                                      SerAspAspSerAlaAlaLeuGluValLeuProProGluLeuGluArg                               210215220                                                                      GlnValGluIleLeuIleArgSerPheProAlaHisHisProValAsp                               225230235240                                                                   LeuAlaAspTrpGluLeuThrGluSerProGluAsnGlyPheSerPhe                               245250255                                                                      AsnThrSerHisSerCysGlyHisLeuValGlnAsnProAspValPhe                               260265270                                                                      AspGlyLysCysTrpLeuSerCysPheLeuGlyGlnSerValGluVal                               275280285                                                                      ArgCysHisGluGluHisLeuAlaAspAlaPheGlyTyrGlnThrLys                               290295300                                                                      TrpGlyValHisGlyLysTyrLeuGlnArgArgLeuGlnValArgGly                               305310315320                                                                   IleArgAlaValValAspProAspGlyProIleHisValGluAlaLeu                               325330335                                                                      SerCysProGlnSerTrpIleArgHisLeuThrLeuAspAspAspVal                               340345350                                                                      ThrProGlyPheValArgLeuThrSerLeuArgIleValProAsnThr                               355360365                                                                      GluProThrThrSerArgIlePheArgPheGlyAlaHisLysTrpTyr                               370375380                                                                      GlyAlaAlaGlyLysArgAlaArgAlaLysArgAlaAlaLysSerGlu                               385390395400                                                                   LysAspSerAlaProThrProLysValAlaLeuProValProThrCys                               405410415                                                                      GlyIleThrThrTyrSerProProThrAspGlySerCysGlyTrpHis                               420425430                                                                      ValLeuAlaAlaIleMetAsnArgMetIleAsnGlyAspPheThrSer                               435440445                                                                      ProLeuThrGlnTyrAsnArgProGluAspAspTrpAlaSerAspTyr                               450455460                                                                      AspLeuValGlnAlaIleGlnCysLeuArgLeuProAlaThrValVal                               465470475480                                                                   ArgAsnArgAlaCysProAsnAlaLysTyrLeuIleLysLeuAsnGly                               485490495                                                                      ValHisTrpGluValGluValArgSerGlyMetAlaProArgSerLeu                               500505510                                                                      SerArgGluCysValValGlyValCysSerGluGlyCysValAlaPro                               515520525                                                                      ProTyrProAlaAspGlyLeuProLysArgAlaLeuGluAlaLeuAla                               530535540                                                                      SerAlaTyrArgLeuProSerAspCysValSerSerGlyIleAlaAsp                               545550555560                                                                   PheLeuAlaAsnProProProGlnGluPheTrpThrLeuAspLysMet                               565570575                                                                      LeuThrSerProSerProGluArgSerGlyPheSerSerLeuTyrLys                               580585590                                                                      LeuLeuLeuGluValValProGlnLysCysGlyAlaThrGluGlyAla                               595600605                                                                      PheIleTyrAlaValGluArgMetLeuLysAspCysProSerSerLys                               610615620                                                                      GlnAlaMetAlaLeuLeuAlaLysIleLysValProSerSerLysAla                               625630635640                                                                   ProSerValSerLeuAspGluCysPheProThrAspValLeuAlaAsp                               645650655                                                                      PheGluProAlaSerGlnGluArgProGlnSerSerGlyAlaAlaVal                               660665670                                                                      ValLeuCysSerProAspAlaLysGluPheGluGluAlaAlaXaaGlu                               675680685                                                                      GluValGlnGluSerGlyHisLysAlaValHisSerAlaLeuLeuAla                               690695700                                                                      GluGlyProAsnAsnGluGlnValGlnValValAlaGlyGluGlnLeu                               705710715720                                                                   LysLeuGlyGlyCysGlyLeuAlaValGlyAsnAlaHisGluGlyAla                               725730735                                                                      LeuValSerAlaGlyLeuIleAsnLeuValGlyGlyAsnLeuSerPro                               740745750                                                                      SerAspProMetLysGluAsnMetLeuAsnSerArgGluAspGluPro                               755760765                                                                      LeuAspLeuSerGlnProAlaProAlaSerThrThrThrLeuValArg                               770775780                                                                      GluGlnThrProAspAsnProGlySerAspAlaGlyAlaLeuProVal                               785790795800                                                                   ThrValArgGluPheValProThrGlyProIleLeuCysHisValGlu                               805810815                                                                      HisCysGlyThrGluSerGlyAspSerSerSerProLeuAspLeuSer                               820825830                                                                      AspAlaGlnThrLeuAspGlnProLeuAsnLeuSerLeuAlaAlaTrp                               835840845                                                                      ProValArgAlaThrAlaSerAspProGlyTrpValHisGlyArgArg                               850855860                                                                      GluProValPheValLysProArgAsnAlaPheSerAspGlyAspSer                               865870875880                                                                   AlaLeuGlnPheGlyGluLeuSerGluSerSerSerValIleGluPhe                               885890895                                                                      AspArgThrLysAspAlaProValValAspAlaProValAspLeuThr                               900905910                                                                      ThrSerAsnGluAlaLeuSerValValAspProPheGluPheAlaGlu                               915920925                                                                      LeuLysArgProArgPheSerAlaGlnAlaLeuIleAspArgGlyGly                               930935940                                                                      ProLeuAlaAspValHisAlaLysIleLysAsnArgValTyrGluGln                               945950955960                                                                   CysLeuGlnAlaCysGluProGlySerArgAlaThrProAlaThrArg                               965970975                                                                      GluTrpLeuAspLysMetTrpAspArgValAspMetLysThrTrpArg                               980985990                                                                      CysThrSerGlnPheGlnAlaGlyArgIleLeuAlaSerLeuLysPhe                               99510001005                                                                    LeuProAspMetIleGlnAspThrProProProValProArgLysAsn                               101010151020                                                                   ArgAlaSerAspAsnAlaGlyLeuLysGlnLeuValAlaGlnTrpAsp                               1025103010351040                                                               ArgLysLeuSerValThrProProProLysProValGlyProValLeu                               104510501055                                                                   AspGlnIleValProProProThrAspIleGlnGlnGluAspValThr                               106010651070                                                                   ProSerAspGlyProProHisAlaProAspPheProSerArgValSer                               107510801085                                                                   ThrGlyGlySerTrpLysGlyLeuMetLeuSerGlyThrArgLeuAla                               109010951100                                                                   GlySerIleSerGlnArgLeuMetThrTrpValPheGluValPheSer                               1105111011151120                                                               HisLeuProAlaPheMetLeuThrLeuPheSerProArgGlySerMet                               112511301135                                                                   AlaProGlyAspTrpLeuPheAlaGlyValValLeuLeuAlaLeuLeu                               114011451150                                                                   LeuCysArgSerTyrProIleLeuGlyCysLeuProLeuLeuGlyVal                               115511601165                                                                   PheSerGlySerLeuArgArgValArgLeuGlyValPheGlySerTrp                               117011751180                                                                   MetAlaPheAlaValPheLeuPheSerThrProSerAsnProValGly                               1185119011951200                                                               SerSerCysAspHisAspSerProGluCysHisAlaGluLeuLeuAla                               120512101215                                                                   LeuGluGlnArgGlnLeuTrpGluProValArgGlyLeuValValGly                               122012251230                                                                   ProSerGlyLeuLeuCysValIleLeuGlyLysLeuLeuGlyGlySer                               123512401245                                                                   ArgTyrLeuTrpHisValLeuLeuArgLeuCysMetLeuAlaAspLeu                               125012551260                                                                   AlaLeuSerLeuValTyrValValSerGlnGlyArgCysHisLysCys                               1265127012751280                                                               TrpGlyLysCysIleArgThrAlaProAlaGluValAlaLeuAsnVal                               128512901295                                                                   PheProPheSerArgAlaThrArgValSerLeuValSerLeuCysAsp                               130013051310                                                                   ArgPheGlnThrProLysGlyValAspProValHisLeuAlaThrGly                               131513201325                                                                   TrpArgGlyCysTrpArgGlyGluSerProIleHisGlnProHisGln                               133013351340                                                                   LysProIleAlaTyrAlaAsnLeuAspGluLysLysMetSerAlaGln                               1345135013551360                                                               ThrValValAlaValProTyrAspProSerGlnAlaIleLysCysLeu                               136513701375                                                                   LysValLeuGlnAlaGlyGlyAlaIleValAspGlnProThrProGlu                               138013851390                                                                   ValValArgValSerGluIleProPheSerAlaProPhePheProLys                               139514001405                                                                   ValProValAsnProAspCysArgValValValAspSerAspThrPhe                               141014151420                                                                   ValAlaAlaValArgCysGlyTyrSerThrAlaGlnLeuXaaLeuGly                               1425143014351440                                                               ArgGlyAsnPheAlaLysLeuAsnGlnThrProProArgAsnSerIle                               144514501455                                                                   SerThrLysThrThrGlyGlyAlaSerTyrThrLeuAlaValAlaGln                               146014651470                                                                   ValSerAlaTrpThrLeuValHisPheIleLeuGlyLeuTrpPheThr                               147514801485                                                                   SerProGlnValCysGlyArgGlyThrAlaAspProTrpCysSerAsn                               149014951500                                                                   ProPheSerTyrProThrTyrGlyProGlyValValCysSerSerArg                               1505151015151520                                                               LeuCysValSerAlaAspGlyValThrLeuProLeuPheSerAlaVal                               152515301535                                                                   AlaGlnLeuSerGlyArgGluValGlyIlePheIleLeuValLeuVal                               154015451550                                                                   SerLeuThrAlaLeuAlaHisArgMetAlaLeuLysAlaAspMetLeu                               155515601565                                                                   ValValPheSerAlaPheCysAlaTyrAlaTrpProMetSerSerTrp                               157015751580                                                                   LeuIleCysPhePheProIleLeuLeuLysTrpValThrLeuHisPro                               1585159015951600                                                               LeuThrMetLeuTrpValHisSerPheLeuValPheCysLeuProAla                               160516101615                                                                   AlaGlyIleLeuSerLeuGlyIleThrGlyLeuLeuTrpAlaIleGly                               162016251630                                                                   ArgPheThrGlnValAlaGlyIleIleThrProTyrAspIleHisGln                               163516401645                                                                   TyrThrSerGlyProArgGlyAlaAlaAlaValAlaThrAlaProGlu                               165016551660                                                                   GlyThrTyrMetAlaAlaValArgArgAlaAlaLeuThrGlyArgThr                               1665167016751680                                                               LeuIlePheThrProSerAlaValGlySerLeuLeuGluGlyAlaPhe                               168516901695                                                                   ArgThrHisLysProCysLeuAsnThrValAsnValValGlySerSer                               170017051710                                                                   LeuGlySerGlyGlyValPheThrIleAspGlyArgArgThrValVal                               171517201725                                                                   ThrAlaAlaHisValLeuAsnGlyAspThrAlaArgValThrGlyAsp                               173017351740                                                                   SerTyrAsnArgMetHisThrPheLysThrAsnGlyAspTyrAlaTrp                               1745175017551760                                                               SerHisAlaAspAspTrpGlnGlyValAlaProValValLysValAla                               176517701775                                                                   LysGlyTyrArgGlyArgAlaTyrTrpGlnThrSerThrGlyValGlu                               178017851790                                                                   ProGlyIleIleGlyGluGlyPheAlaPheCysPheThrAsnCysGly                               179518001805                                                                   AspSerGlySerProValIleSerGluSerGlyAspLeuIleGlyIle                               181018151820                                                                   HisThrGlySerAsnLysLeuGlySerGlyLeuValThrThrProGlu                               1825183018351840                                                               GlyGluThrCysThrIleLysGluThrLysLeuSerAspLeuSerArg                               184518501855                                                                   HisPheAlaGlyProSerValProLeuGlyAspIleLysLeuSerPro                               186018651870                                                                   AlaIleIleProAspValThrSerIleProSerAspLeuAlaSerLeu                               187518801885                                                                   LeuAlaSerValProValValGluGlyGlyLeuSerThrValGlnLeu                               189018951900                                                                   LeuCysValPhePheLeuLeuTrpArgMetMetGlyHisAlaTrpThr                               1905191019151920                                                               ProIleValAlaValGlyPhePheLeuLeuAsnGluIleLeuProAla                               192519301935                                                                   ValLeuValArgAlaValPheSerPheAlaLeuPheValLeuAlaTrp                               194019451950                                                                   AlaThrProTrpSerAlaGlnValLeuMetIleArgLeuLeuThrAla                               195519601965                                                                   SerLeuAsnArgAsnLysLeuSerLeuAlaPheTyrAlaLeuGlyGly                               197019751980                                                                   ValValGlyLeuAlaAlaGluIleGlyThrPheAlaGlyArgLeuSer                               1985199019952000                                                               GluLeuSerGlnAlaLeuSerThrTyrCysPheLeuProArgValLeu                               200520102015                                                                   AlaMetThrSerCysValProThrIleIleIleGlyGlyLeuHisThr                               202020252030                                                                   LeuGlyValIleLeuTrpXaaPheLysTyrArgCysLeuHisAsnMet                               203520402045                                                                   LeuValGlyAspGlySerPheSerSerAlaPhePheLeuArgTyrPhe                               205020552060                                                                   AlaGluGlyAsnLeuArgLysGlyValSerGlnSerCysGlyMetAsn                               2065207020752080                                                               AsnGluSerLeuThrAlaAlaLeuAlaCysLysLeuSerGlnAlaAsp                               208520902095                                                                   LeuAspPheLeuSerSerLeuThrAsnPheLysCysPheValSerAla                               210021052110                                                                   SerAsnMetLysAsnAlaAlaGlyGlnTyrIleGluAlaAlaTyrAla                               211521202125                                                                   LysAlaLeuArgGlnGluLeuAlaSerLeuValGlnIleAspLysMet                               213021352140                                                                   LysGlyValLeuSerLysLeuGluAlaPheAlaGluThrAlaThrPro                               2145215021552160                                                               SerLeuAspIleGlyAspValIleValLeuLeuGlyGlnHisProHis                               216521702175                                                                   GlySerIleLeuAspIleAsnValGlyThrGluArgLysThrValSer                               218021852190                                                                   ValGlnGluThrArgSerLeuGlyGlySerLysPheSerValCysThr                               219522002205                                                                   ValValSerAsnThrProValAspAlaXaaThrGlyIleProLeuGln                               221022152220                                                                   ThrProThrProLeuPheGluAsnGlyProArgHisArgSerGluGlu                               2225223022352240                                                               AspAspLeuLysValGluArgMetLysLysHisCysValSerLeuGly                               224522502255                                                                   PheHisAsnIleAsnGlyLysValTyrCysLysIleTrpAspLysSer                               226022652270                                                                   ThrGlyAspThrPheTyrThrAspAspSerArgTyrThrGlnAspHis                               227522802285                                                                   AlaPheGlnAspArgSerAlaAspTyrArgAspArgAspTyrGluGly                               229022952300                                                                   ValGlnThrThrProGlnGlnGlyPheAspProLysSerGluThrPro                               2305231023152320                                                               ValGlyThrValValIleGlyGlyIleThrTyrAsnArgTyrLeuIle                               232523302335                                                                   LysGlyLysGluValLeuValProLysProAspAsnCysLeuGluAla                               234023452350                                                                   AlaLysLeuSerLeuGluGlnAlaLeuAlaGlyMetGlyGlnThrCys                               235523602365                                                                   AspLeuThrAlaAlaGluValGluLysLeuLysArgIleIleSerGln                               237023752380                                                                   LeuGlnGlyLeuThrThrGluGlnAlaLeuAsnCys                                           238523902395                                                                   (2) INFORMATION FOR SEQ ID NO:3:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1463 amino acids                                                   (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                        ThrGlyPheLysLeuLeuAlaAlaSerGlyLeuThrArgCysGlyArg                               151015                                                                         GlyGlyLeuValValThrGluThrAlaValLysIleIleLysTyrHis                               202530                                                                         SerArgThrPheThrLeuGlyProLeuAspLeuLysValThrSerGlu                               354045                                                                         ValGluValLysLysSerThrGluGlnGlyHisAlaValValAlaAsn                               505560                                                                         LeuCysSerGlyValIleLeuMetArgProHisProProSerLeuVal                               65707580                                                                       AspValLeuLeuLysProGlyLeuAspThrIleProGlyIleGlnPro                               859095                                                                         GlyHisGlyAlaGlyAsnMetGlyValAspGlySerIleTrpAspPhe                               100105110                                                                      GluThrAlaProThrLysAlaGluLeuGluLeuSerLysGlnIleIle                               115120125                                                                      GlnAlaCysGluValArgArgGlyAspAlaProAsnLeuGlnLeuPro                               130135140                                                                      TyrLysLeuTyrProValArgGlyAspProGluArgHisLysGlyArg                               145150155160                                                                   LeuIleAsnThrArgPheGlyAspLeuProTyrLysThrProGlnAsp                               165170175                                                                      ThrLysSerAlaIleHisAlaAlaCysCysLeuHisProAsnGlyAla                               180185190                                                                      ProValSerAspGlyLysSerThrLeuGlyThrThrLeuGlnHisGly                               195200205                                                                      PheGluLeuTyrValProThrValProTyrSerValMetGluTyrLeu                               210215220                                                                      AspSerArgProAspThrProPheMetCysThrLysHisGlyThrSer                               225230235240                                                                   LysAlaAlaAlaGluAspLeuGlnLysTyrAspLeuSerThrGlnGly                               245250255                                                                      PheValLeuProGlyValLeuArgLeuValArgArgPheIlePheGly                               260265270                                                                      HisIleGlyLysAlaProProLeuPheLeuProSerThrTyrProAla                               275280285                                                                      LysAsnSerMetAlaGlyIleAsnGlyGlnArgPheProThrLysAsp                               290295300                                                                      ValGlnSerIleProGluIleAspGluMetCysAlaArgAlaValLys                               305310315320                                                                   GluAsnTrpGlnThrValThrProCysThrLeuLysLysGlnTyrCys                               325330335                                                                      SerLysProLysThrArgThrIleLeuGlyThrAsnAsnPheIleAla                               340345350                                                                      LeuAlaHisArgSerAlaLeuSerGlyValThrGlnAlaPheMetLys                               355360365                                                                      LysAlaTrpLysSerProIleAlaLeuGlyLysAsnLysPheLysGlu                               370375380                                                                      LeuHisCysThrValAlaGlyArgCysLeuGluAlaAspLeuAlaSer                               385390395400                                                                   CysAspArgSerThrProAlaIleValArgTrpPheValAlaAsnLeu                               405410415                                                                      LeuTyrGluLeuAlaGlyCysGluGluTyrLeuProSerTyrValLeu                               420425430                                                                      AsnCysCysHisAspLeuValAlaThrGlnAspGlyAlaPheThrLys                               435440445                                                                      ArgGlyGlyLeuSerSerGlyAspProValThrSerValSerAsnThr                               450455460                                                                      ValTyrSerLeuValIleTyrAlaGlnHisMetValLeuSerAlaLeu                               465470475480                                                                   LysMetGlyHisGluIleGlyLeuLysPheLeuGluGluGlnLeuLys                               485490495                                                                      PheGluAspLeuLeuGluIleGlnProMetLeuValTyrSerAspAsp                               500505510                                                                      LeuValLeuTyrAlaGluArgProXaaPheProAsnTyrHisTrpTrp                               515520525                                                                      ValGluHisLeuAspLeuMetLeuGlyPheArgThrAspProLysLys                               530535540                                                                      ThrValIleThrAspLysProSerPheLeuGlyCysArgIleGluAla                               545550555560                                                                   GlyArgGlnLeuValProAsnArgAspArgIleLeuAlaAlaLeuAla                               565570575                                                                      TyrHisMetLysAlaGlnAsnAlaSerGluTyrTyrAlaSerAlaAla                               580585590                                                                      AlaIleLeuMetAspSerCysAlaCysIleAspHisAspProGluTrp                               595600605                                                                      TyrGluAspLeuIleCysGlyIleAlaArgCysAlaArgGlnAspGly                               610615620                                                                      TyrSerPheProGlyProAlaPhePheMetSerMetTrpGluLysLeu                               625630635640                                                                   ArgSerHisAsnGluGlyLysLysPheArgHisCysGlyIleCysAsp                               645650655                                                                      AlaLysAlaAspTyrAlaSerAlaCysGlyLeuAspLeuCysLeuPhe                               660665670                                                                      HisSerHisPheHisGlnHisCysXaaValThrLeuSerCysGlyHis                               675680685                                                                      HisAlaGlySerLysGluCysSerGlnCysGlnSerProValGlyAla                               690695700                                                                      GlyArgSerProLeuAspAlaValLeuLysGlnIleProTyrLysPro                               705710715720                                                                   ProArgThrValIleMetLysValGlyAsnLysThrThrAlaLeuAsp                               725730735                                                                      ProGlyArgTyrGlnSerArgArgGlyLeuValAlaValLysArgGly                               740745750                                                                      IleAlaGlyAsnGluValAspLeuSerAspXaaAspTyrGlnValVal                               755760765                                                                      ProLeuLeuProThrCysLysAspIleAsnMetValLysValAlaCys                               770775780                                                                      AsnValLeuLeuSerLysPheIleValGlyProProGlySerGlyLys                               785790795800                                                                   ThrThrTrpLeuLeuSerGlnValGlnAspAspAspValIleTyrXaa                               805810815                                                                      ProThrHisGlnThrMetPheAspIleValSerAlaLeuLysValCys                               820825830                                                                      ArgTyrSerIleProGlyAlaSerGlyLeuProPheProProProAla                               835840845                                                                      ArgSerGlyProTrpValArgLeuIleAlaSerGlyHisValProGly                               850855860                                                                      ArgValSerTyrLeuAspGluAlaGlyTyrCysAsnHisLeuAspIle                               865870875880                                                                   LeuArgLeuLeuSerLysThrProLeuValCysLeuGlyAspLeuGln                               885890895                                                                      GlnLeuHisProValGlyPheAspSerTyrCysTyrValPheAspGln                               900905910                                                                      MetProGlnLysGlnLeuThrThrIleTyrArgPheGlyProAsnIle                               915920925                                                                      CysAlaArgIleGlnProCysTyrArgGluLysLeuGluSerLysAla                               930935940                                                                      ArgAsnThrArgValValPheThrThrArgProValAlaPheGlyGln                               945950955960                                                                   ValLeuThrProTyrHisLysAspArgIleGlySerAlaIleThrIle                               965970975                                                                      AspSerSerGlnGlyAlaThrPheAspIleValThrLeuHisLeuPro                               980985990                                                                      SerProLysSerLeuAsnLysSerArgAlaLeuValAlaIleThrArg                               99510001005                                                                    AlaArgHisGlyLeuPheIleTyrAspProHisAsnGlnLeuGlnGlu                               101010151020                                                                   PhePheAsnLeuThrProGluArgThrAspCysAsnLeuValPheSer                               1025103010351040                                                               ArgGlyAspGluLeuValValLeuAsnAlaAspAsnAlaValThrThr                               104510501055                                                                   ValAlaLysAlaLeuGluThrGlyProSerArgPheArgValSerAsp                               106010651070                                                                   ProArgCysLysSerLeuLeuAlaAlaCysSerAlaSerLeuGluGly                               107510801085                                                                   SerCysMetProLeuProGlnValAlaHisAsnLeuGlyPheTyrPhe                               109010951100                                                                   SerProAspSerProThrPheAlaProLeuProLysGluLeuAlaPro                               1105111011151120                                                               HisTrpProValValThrHisGlnAsnAsnArgAlaTrpProAspArg                               112511301135                                                                   LeuValAlaSerMetArgProIleAspAlaArgTyrSerLysProMet                               114011451150                                                                   ValGlyAlaGlyTyrValValGlyProSerThrPheLeuGlyThrPro                               115511601165                                                                   GlyValValSerTyrTyrLeuThrLeuTyrIleArgGlyGluProGln                               117011751180                                                                   AlaLeuProGluThrLeuValSerThrGlyArgIleAlaThrAspCys                               1185119011951200                                                               ArgGluTyrLeuAspAlaAlaGluGluGluAlaAlaLysGluLeuPro                               120512101215                                                                   HisAlaPheIleGlyAspValLysGlyThrThrValGlyGlyCysHis                               122012251230                                                                   HisIleThrSerLysTyrLeuProArgSerLeuProLysAspSerVal                               123512401245                                                                   AlaValValGlyValSerSerProGlyArgAlaAlaLysAlaValCys                               125012551260                                                                   ThrLeuThrAspValTyrLeuProGluLeuArgProTyrLeuGlnPro                               1265127012751280                                                               GluThrAlaSerLysCysTrpLysLeuLysLeuAspPheArgAspVal                               128512901295                                                                   ArgLeuMetValTrpLysGlyAlaThrAlaTyrPheGlnLeuGluGly                               130013051310                                                                   LeuThrTrpSerAlaLeuProAspTyrAlaArgXaaIleGlnLeuPro                               131513201325                                                                   LysAspAlaValValTyrIleAspProCysIleGlyProAlaThrAla                               133013351340                                                                   AsnArgLysValValArgThrThrAspTrpArgAlaAspLeuAlaVal                               1345135013551360                                                               ThrProTyrAspTyrGlyAlaGlnAsnIleLeuThrThrAlaTrpPhe                               136513701375                                                                   GluAspLeuGlyProGlnTrpLysIleLeuGlyLeuGlnProPheArg                               138013851390                                                                   ArgAlaPheGlyPheGluAsnThrGluAspTrpAlaIleLeuAlaArg                               139514001405                                                                   ArgMetAsnAspGlyLysAspTyrThrAspTyrAsnTrpAsnCysVal                               141014151420                                                                   ArgGluArgProHisAlaIleTyrGlyArgAlaArgAspHisThrTyr                               1425143014351440                                                               HisPheAlaProGlyThrGluLeuGlnValGluLeuGlyLysProArg                               144514501455                                                                   LeuProProGlyGlnValPro                                                          1460                                                                           (2) INFORMATION FOR SEQ ID NO:4:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 249 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                        MetGlnTrpGlyHisCysGlyValLysSerAlaSerCysSerTrpThr                               151015                                                                         ProSerLeuSerSerLeuLeuValTrpLeuIleLeuXaaPheSerLeu                               202530                                                                         ProTyrCysLeuGlySerProSerGlnAspGlyTyrTrpSerPhePhe                               354045                                                                         SerGluTrpPheAlaProArgPheSerValArgAlaLeuProPheThr                               505560                                                                         LeuProAsnTyrArgArgSerTyrGluGlyLeuLeuProAsnCysArg                               65707580                                                                       ProAspValProGlnPheAlaValLysHisProLeuXaaMetPheTrp                               859095                                                                         HisMetArgValSerHisLeuIleAspGluXaaValSerArgArgIle                               100105110                                                                      TyrGlnThrMetGluHisSerGlyGlnAlaAlaTrpLysGlnValVal                               115120125                                                                      GlyGluAlaThrLeuThrLysLeuSerGlyLeuAspIleValThrHis                               130135140                                                                      PheGlnHisLeuAlaAlaValGluAlaAspSerCysArgPheLeuSer                               145150155160                                                                   SerArgLeuValMetLeuLysAsnLeuAlaValGlyAsnValSerLeu                               165170175                                                                      GlnTyrAsnThrThrLeuAspArgValGluLeuIlePheProThrPro                               180185190                                                                      GlyThrArgProLysLeuThrAspPheArgGlnTrpLeuIleSerVal                               195200205                                                                      HisAlaSerIlePheSerSerValAlaSerSerValThrLeuPheIle                               210215220                                                                      ValLeuTrpLeuArgIleProAlaLeuArgTyrValPheGlyPheHis                               225230235240                                                                   TrpProThrAlaThrHisHisSerSer                                                    245                                                                            (2) INFORMATION FOR SEQ ID NO:5:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 265 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                        MetAlaHisGlnCysAlaArgPheHisPhePheLeuCysGlyPheIle                               151015                                                                         CysTyrLeuValHisSerAlaLeuAlaSerAsnSerSerSerThrLeu                               202530                                                                         CysPheTrpPheProLeuAlaHisGlyAsnThrSerPheGluLeuThr                               354045                                                                         IleAsnTyrThrIleCysMetProCysSerThrSerGlnAlaAlaArg                               505560                                                                         GlnArgLeuGluProGlyArgAsnMetTrpCysLysIleGlyHisAsp                               65707580                                                                       ArgCysGluGluArgAspHisAspGluLeuLeuMetSerIleProSer                               859095                                                                         GlyTyrAspAsnLeuLysLeuGluGlyTyrTyrAlaTrpLeuAlaPhe                               100105110                                                                      LeuSerPheSerTyrAlaAlaGlnPheHisProGluLeuPheGlyIle                               115120125                                                                      GlyAsnValSerArgValPheValAspLysArgHisGlnPheIleCys                               130135140                                                                      AlaGluHisAspGlyHisAsnSerThrValSerThrGlyHisAsnIle                               145150155160                                                                   SerAlaLeuTyrAlaAlaTyrTyrHisHisGlnIleAspGlyGlyAsn                               165170175                                                                      TrpPheHisLeuGluTrpLeuArgProLeuPheSerSerTrpLeuVal                               180185190                                                                      LeuAsnIleSerTrpPheLeuArgArgSerProValSerProValSer                               195200205                                                                      ArgArgIleTyrGlnIleLeuArgProThrArgProArgLeuProVal                               210215220                                                                      SerTrpSerPheArgThrSerIleValSerAspLeuThrGlySerGln                               225230235240                                                                   GlnArgLysArgLysPheProSerGluSerArgProAsnValValLys                               245250255                                                                      ProSerValLeuProSerThrSerArg                                                    260265                                                                         (2) INFORMATION FOR SEQ ID NO:6:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 183 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                        MetAlaAlaAlaThrLeuPhePheLeuAlaGlyAlaGlnHisIleMet                               151015                                                                         ValSerGluAlaPheAlaCysLysProCysPheSerThrHisLeuSer                               202530                                                                         AspIleGluThrAsnThrThrAlaAlaAlaGlyPheMetValLeuGln                               354045                                                                         AspIleAsnCysPheArgProHisGlyValSerAlaAlaGlnGluLys                               505560                                                                         IleSerPheGlyLysSerSerGlnCysArgGluAlaValGlyThrPro                               65707580                                                                       GlnTyrIleThrIleThrAlaAsnValThrAspGluSerTyrLeuTyr                               859095                                                                         AsnAlaAspLeuLeuMetLeuSerAlaCysLeuPheTyrAlaSerGlu                               100105110                                                                      MetSerGluLysGlyPheLysValIlePheGlyAsnValSerGlyVal                               115120125                                                                      ValSerAlaCysValAsnPheThrAspTyrValAlaHisValThrGln                               130135140                                                                      HisThrGlnGlnHisHisLeuValIleAspHisIleArgLeuLeuHis                               145150155160                                                                   PheLeuThrProSerAlaMetArgTrpAlaThrThrIleAlaCysLeu                               165170175                                                                      PheAlaIleLeuLeuAlaIle                                                          180                                                                            (2) INFORMATION FOR SEQ ID NO:7:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 201 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                        MetArgCysSerHisLysLeuGlyArgPheLeuThrProHisSerCys                               151015                                                                         PheTrpTrpLeuPheLeuLeuCysThrGlyLeuSerTrpSerPheAla                               202530                                                                         AspGlyAsnGlyAspSerSerThrTyrGlnTyrIleTyrAsnLeuThr                               354045                                                                         IleCysGluLeuAsnGlyThrAspTrpLeuSerSerHisPheGlyTrp                               505560                                                                         AlaValGluThrPheValLeuTyrProValAlaThrHisIleLeuSer                               65707580                                                                       LeuGlyPheLeuThrThrSerHisPhePheAspAlaLeuGlyLeuGly                               859095                                                                         AlaValSerThrAlaGlyPheValGlyGlyArgTyrValLeuCysSer                               100105110                                                                      ValTyrGlyAlaCysAlaPheAlaAlaPheValCysPheValIleArg                               115120125                                                                      AlaAlaLysAsnCysMetAlaCysArgTyrAlaArgThrArgPheThr                               130135140                                                                      AsnPheIleValAspAspArgGlyArgValHisArgTrpLysSerPro                               145150155160                                                                   IleValValGluLysLeuGlyLysAlaGluValAspGlyAsnLeuVal                               165170175                                                                      ThrIleLysHisValValLeuGluGlyValLysAlaGlnProLeuThr                               180185190                                                                      ArgThrSerAlaGluGlnTrpGluAla                                                    195200                                                                         (2) INFORMATION FOR SEQ ID NO:8:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 173 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:                                        MetGlyGlyLeuAspAspPheCysAsnAspProIleAlaAlaGlnLys                               151015                                                                         LeuValLeuAlaPheSerIleThrTyrThrProIleMetIleTyrAla                               202530                                                                         LeuLysValSerArgGlyArgLeuLeuGlyLeuLeuHisIleLeuIle                               354045                                                                         PheLeuAsnCysSerPheThrPheGlyTyrMetThrTyrValHisPhe                               505560                                                                         GlnSerThrAsnArgValAlaLeuThrLeuGlyAlaValValAlaLeu                               65707580                                                                       LeuTrpGlyValTyrSerPheThrGluSerTrpLysPheIleThrSer                               859095                                                                         ArgCysArgLeuCysCysLeuGlyArgArgTyrIleLeuAlaProAla                               100105110                                                                      HisHisValGluSerAlaAlaGlyLeuHisSerIleSerAlaSerGly                               115120125                                                                      AsnArgAlaTyrAlaValArgLysProGlyLeuThrSerValAsnGly                               130135140                                                                      ThrLeuValProGlyLeuArgSerLeuValLeuGlyGlyLysArgAla                               145150155160                                                                   ValLysArgGlyValValAsnLeuValLysTyrGlyArg                                        165170                                                                         (2) INFORMATION FOR SEQ ID NO:9:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 128 amino acids                                                    (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:                                        MetAlaGlyLysAsnGlnSerGlnLysLysLysLysSerThrAlaPro                               151015                                                                         MetGlyAsnGlyGlnProValAsnGlnLeuCysGlnLeuLeuGlyAla                               202530                                                                         MetIleLysSerGlnArgGlnGlnProArgGlyGlyGlnXaaLysLys                               354045                                                                         LysLysProGluLysProHisPheProLeuAlaAlaGluAspAspIle                               505560                                                                         ArgHisHisLeuThrGlnThrGluArgSerLeuCysLeuGlnSerIle                               65707580                                                                       GlnThrAlaPheAsnGlnGlyAlaGlyThrAlaXaaLeuSerSerSer                               859095                                                                         GlyLysValSerPheGlnValGluPheMetLeuProValAlaHisThr                               100105110                                                                      ValArgLeuIleArgValThrSerThrSerAlaSerGlnGlyAlaSer                               115120125                                                                      __________________________________________________________________________ 

We claim:
 1. An isolated causative agent of Mystery Swine Disease identified as deposit number I-1102, deposited Jun. 5, 1991 with the Institut Pasteur, Paris, France.
 2. A composition of matter comprising virus identified as Institut Pasteur deposit number I-1102.
 3. A composition of matter in accordance with claim 2 wherein said virus is killed.
 4. A vaccine composition comprising a virus having all the attributes of Lelystad Agent deposited Jun. 5, 1991 with the Institut Pasteur, Paris, France, deposit number I-1102, and a suitable carrier.
 5. A vaccine composition in accordance with claim 4 wherein the virus is killed.
 6. The vaccine composition of claim 4 further comprising an adjuvant.
 7. The vaccine composition of claim 5 further comprising an adjuvant.
 8. Isolated Lelystad Agent comprising a virus, said virus characterized in being sensitive to chloroform and having a size smaller than 200 nanometers, said virus further being immunoreactive with serum antibodies of a sow, said serum antibodies obtained by:a) intranasally inoculating the sow with two milliliters of the virus identified as deposit number I-1102, deposited Jun. 5, 1991 with the Institut Pasteur, Paris, France (at passage level 3, titer 10⁴.8 TCID₅₀ /milliliter); and b) collecting serum antibodies from the thus inoculated sow after 25 to 33 days.
 9. The isolated Lelystad Agent of claim 8 wherein said virus has been inactivated.
 10. The isolated Lelystad Agent of claim 9 in combination with an adjuvant. 